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ABSTRACT
EFFECTS OF COMPLEMENT C5A IN TUMOR PROGRESSION AND THE
LOCAL TUMOR MICROENVIRONMENT
Lacey Jo Gunn
June 16, 2011

Monoclonal antibodies directed toward tumor associated antigens are FDA
approved anticancer reagents used commonly in the clinic. Administered antibodies
initiate tumor cell death through several mechanisms. Improving immune mediated
mechanisms, antibody-dependent cellular cytotoxicity (ADCC) and complementdependent cytotoxicity (CDC) may improve treatment success. However, in many
tumors, complement activation and propagation is limited by tumor cell overexpression
of complement regulatory proteins (CRPs). Thus, introduction of complement
components into the tumor, specifically anaphylatoxin C5a, may provide a key strategy to
improve existing, approved anti-tumor treatment. Currently the role of C5a in the tumor
remains unclear.
The receptor for C5a, C5aR, is expressed predominantly by neutrophils and cells
of the innate immune system. The human ovarian adenocarcinoma cell line, SKOV -3,
was demonstrated to overexpress CRP CD55 which inhibits the release of C5a. As a
result, a SCID xenograft model was established to determine the effect of C5a in the
tumor microenvironment. The model allowed study of the effect of C5a on innate
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immune cells exclusively, as well as the introduction of C5a in the presence of CD55. In
vivo and in vitro studies were performed to clarify the controversial role of C5a in the
tumor and the effect on innate immune cell phenotype and cytotoxic function.
The release of local C5a from tumor cells led to enhanced infiltration of
macrophages and NK cells, and neutrophils as related to tumor size. C5a also increased
production of proinflammatory and tumor cytostatic mediator TGF-~ by infiltrating
macrophages. Furthermore, C5a downregulated the generation of iNOS and arginase by
infiltrating cells, tumor cell VEGF and total tumor TNF-a. production. In vitro studies
provided support of C5a significantly improving cytotoxicity of NK cells against tumor
cells, and significantly reducing immunosuppression by infiltrating neutrophils.
Importantly, C5a in the tumor caused no major systemic alterations or adverse side
effects.
The result of local C5a release into the tumor microenvironment had a dramatic effect on
tumor growth through the recruitment and activation of innate immune cells. C5a altered
phenotypes of infiltrating immune cells toward anti-tumorigenic and improved tumor cell
cytotoxicity. Based on the findings of C5a in the SKOV -3 xenograft model in the context
of published work involving C5a in the tumor, concentration of local C5a is proposed to
be critical in determining its role in tumor progression.
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CHAPTERl
THE COMPLEMENT SYSTEM: A CRITICAL ARM OF THE IMMUNE
RESPONSE

Complement activation:

Complement is an important component of the immune system, and activation of
the complement cascade involves a variety of proteins, including opsonins, convertases,
pore-forming proteins, anaphylatoxins, and regulatory proteins. The events producing and
releasing these proteins results in the propagation and control of a multi-faceted system
by which to contribute and perpetuate immune reactions during an effective immune
response [1]. Activation of complement can occur via the classical pathway following the
aggregation of antigen-antibody complexes, lectin pathway in the case of infection with
microbes expressing smface mannose molecules, and alternative pathway which occurs
spontaneously or on the surface of foreign substances or molecules [2]. Although
initiation of the cascade can vary, all three pathways converge in the formation of the C3
protein.
The generation and subsequent cleavage of C3 leads to the three effector
mechanisms of the complement system: binding and formation of the membrane attack
complex (MAC) which can directly lyse targeted cells, deposition of iC3b on cells or
microbes decorating them as targets for destruction by cells of the innate immune system,
and the release of anaphylatoxins which chemoattract and activate immune cells to the
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desired location [1]. Anaphylatoxins are responsible for converting danger signals from
the fluid phase of the host into an orchestrated cellular response [3]. Anaphylatoxin C5a,
a potent inflammatory mediator is released into the local environment and is responsible
for several functions. C5a chemoattracts cells of the innate immune system to the site of
infection or damage [3, 4], activates immune cells upon interaction with the C5a receptor
(C5aR) resulting in oxidative burst in neutrophils, phagocytosis augmentation, and
enzymatic granule release, as well as vasodilation of local blood vessels to enhance
immune cell entry and exchange of cells and factors from the circulation into the local
infected or injured tissue [3, 5]. C5a is quickly degraded by carboxypeptidases available
abundantly in tissues and serum by cleaving the carboxy-terminal arginine residue to C5a
desArg [1]. The degradation product maintains some chemotactic and proinflammatory

properties of C5a but the potency is greatly reduced [3].
As a result of the extensive and potent effects of complement activation, the
complement cascade is highly regulated at several levels by complement regulatory
proteins (CRPs) which can effectively dampen the intense pro inflammatory response
initiated by complement activation and the release of C5a. CRPs are expressed on the
membranes of normal cells and can also exist in soluble form [6, 7] to limit the extent of
complement activation and reduce normal/healthy cell damage. CD35, CD46, CD55, and
CD59 are all known members of the regulators of complement activation family [7].
CD35 (complement receptor 1 CRl) is expressed on haematopoeitic cells, monocytes,
and granulocytes; it regulates the activity of C3 convertase. CD46 (membrane cofactor
protein) also regulates C3 convertase activity and is expressed broadly with the exception
of erythrocytes. CD59 and CD55 are membrane proteins expressed normally on nearly all
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cells of the body. CD59 (Protectin) prevents the formation of the MAC, limiting cell lysis
of complement opsonized celis, also a function of CD46 and CD55. CD55 (decayaccelerating factor) is responsible for the accelerated dissolution of C3 convertase, and as
a result, the C5 convertase. Rather than proteolytic ally, in the case for other regulatory
proteins, CD55 accelerates the dissociation of the components of the convertases
eliminating release of anaphylatoxins [7].
Diagram 1. Complement Cascade
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Diagram 1. A simplified version of the complement cascade highlighting important
proteins and events. There are three pathways by which the cascade may be initiated,
but all pathways converge on the central C3 protein and the generation of unique C3
convertases. The enzyme activity leads to the release of C3a and C3b. C3b binds to
the surface of a complement targeted cell or pathogen and can be inactivated to the
iC3b form which opsonizes the target for recognition and destruction by important
immune cells. Additionally, C3b is important in the generation of the C5 convertase.
Activity of C5 convertase results in the release of C5a and C5b. C5b binds to the
surface of the complement targeted cell, and is the initial step of the formation of the
MAC which forms pores and destroys the target. C3a and C5a are anaphlytoxins
important in initiating many characteristics of inflamed tissue: vasodilation, increased
temperature, and recruitment and activation of immune effector cells.
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CHAPTER 2
THE COMPLEX RELATIONSHIP BETWEEN ARISING TUMORS AND THE
IMMUNE SYSTEM

Inflammation and Cancer:
Immunosurveillance:

Immunosurveillance refers to the prevention of cancer development as a result of
immune cell recognition and elimination of transforming cells. Various cells and
components of the innate immune system possess the capacity to recognize and eliminate
cancerous cells [8] (Diagram 2), and have been implicated in protecting the host against
tumor development in many research models, as well as human cases [3, 8-11]. Three
main results of immune cell activity have been demonstrated as being critical to
preventing the development of cancer in the host: protection against viral infection,
resolution of inflammation in order to dissolve an inflammatory microenvironment ideal
for tumor development, and destruction of tumor cells based on tumor cell expression of
innate immune cell activating receptors [11]. The innate immune system, including the
complement system, has the capacity to recognize alterations produced by transformed
cells and destroy these cells [3, 11]. However, as the defined mechanism of
"immunoediting" illustrates, only a few tumor cells under the scrutiny and attack of
immune cells need adapt the features necessary to evade destruction and take a strong
hold in the host [11, 12]. In the case of this event, these transformed cells are able to

4

escape detection and begin growing while using the inflammatory mediators produced
locally to fuel progression [9, 12]. As with any group of growing cells, growth factors,
inhibition of apoptosis, and supply of blood are required. Cells of the immune system are
recruited and stimulated by tumor products to aid in the acquisition of these vital survival
and growth requirements [9, 12, 13] (Diagram 2, adapted from).
Elimination:

Equilibrium:

&cape:

Immune cells recognize
and destroy mutated
tumor cells

Mutation(s) of tumor
cells not recognized
by immune cells. cells
evade destruction and

Mutations of evading
tumor cells result in
enhanced tumor growth.
further evasion of immune cells.
and even recruitment of immune
cells and their functions for tumor growth

T cells:
CD8, CD4,16

1. Clone evades
immune
destruction and
grows

1. Clone develops
further immune evasive
or manipulative
characteristics and is
established

Normal cell§-tumor cells
eliminated

Diagram 2: Tumor destruction or growth in the presence of host immune cells.
During the elimination stage, mutating or transforming host cells are recognized and
destroyed by multiple cells of the immune system. This results in restoration of normal
cell growth in the tissue free of cancerous cells. Alternatively, mutating cells my
develop a mutation which results in evasion of immune cell recognition and
subsequent destruction, and these transformed cells grow in equilibrium with normal
host cells in the presence of immune cells. However, an additional mutation leading to
enhanced growth or recruitment of immune cells in order to elicit their properties for
tumor growth rather than destruction occurs during escape, and cancer develops in the
host.
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Immune cell manipulation by tumor:

Cancer often develops in adults following undetected/asymptomatic inflammatory
disease [14]. When the vast majority of cancer patients present clinically they have an
established tumor that successfully evaded and/or enlisted immune cells responding to
the tumor to avoid destruction and promote its growth. Tumor and associated stromal
cells respond to proinflammatory factors produced locally by infiltrating immune cells,
which leads to tumor production of mediators, such as cytokines, inhibitory molecules, or
dysregulation of receptors, to effectively alter the immune response in the tumor
microenvironment to benefit tumor growth [9, 13, 15]. The generation of an environment
that fosters a continuous, tumor promoting response by infiltrating immune cells and
tumor cells, is thought to be perpetuated by the environmental conditions established
mimicking chronic inflammation [13]. The properties of inflammation efficiently
promote and protect the tumor including ischemia, edema, immune cell infiltration, and
new blood vessel formation for delivery of additional nutrients [8, 12, 14]. Immune cells
in the tumor are required for the construction of new blood vessels and tumor growth
enhancement [14].
Immunotherapy:

Debate over the role of immune cells in cancer destruction and prevention lasted
decades, but it is well established that the immune system plays an important role in the
prevention of cancer development [11]. In the more recent decades of cancer research,
manipulating and enhancing immune cell migration and anti-tumor activities has been a
main focus of immunologists. Many methods of immunotherapy in cancer have targeted
developing and enhancing the tumor specific T cell response through the administration
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of activated dendritic cell vaccines, or administration of an individual's T cells following
culture and expansion with tumor associated antigens (TAAs) [16]. Whereas these
methods seem promising, they are complicated, expensive, and limited by requirements
of the individual patient's as a cell source [16]. These restrictions to successful treatment
have encouraged shifting the focus to other immunological targets for enhancing an antitumor response [11]. Innate immune cells are attractive targets of the immune system as a
result of large circulating numbers, and the lack of prerequisite priming event(s) to be
effectively cytotoxic [10]. In the case of macrophages, subsets are known to play an
important role in tumor growth and progression [13, 17], targeting and reversing this protumorigenic phenotype may prove beneficial in providing additional modes of
immunotherapy [18, 19].

Complement and Cancer:
The complement system can discern alterations of endogenous molecules that are
related to tumors and become activated [3]. In several tumor models, complement
proteins have been indicated in tumor regression [20-22]. Great potential has been shown
for components of the complement cascade being targeted or incorporated into cancer
patients' treatment regimes with anti-tumor monoclonal antibodies to improve the most
common and nearly only anticancer reagents approved by the FDA [4, 23]. Rituximab is
a monoclonal antibody against CD20, and is used in the frontline of treatment of patients
with non-Hodgkin's B cell lymphoma (NHL). The mechanism ofrituximab action
against tumor cells is suspected to include complement-dependent cytotoxicity (CDC)
and antibody-dependent cellular cytotoxicity (ADCC) [24,25]. Therefore, complement
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activation and propagation of the complement cascade is critical to the therapeutic
efficacy of rituximab treatment and other monoclonal anti-tumor antibody therapies [24,
26-28]. The opsonization of cells following rituximab or other antibody binding and
complement activation is critical to leading to MAC formation on and innate immune cell
destruction of targeted cells [24, 28, 29]. In mouse xenograft and syngeneic tumor
models, cobra venom factor treatment to deplete complement and Clq knockout mice
treated with rituximab demonstrated a significant reduction of the anti-tumor properties
[26-28]. It is apparent from the above studies that regardless of whether or not the tumor
is targeted for lysis via the MAC formation on the membrane, opsonization of the tumor
cells by C3b or iC3b deposition, or release of C5a to recruit and activate innate immune
cells leading to subsequent destruction of the tumor, activation of complement proves to
be an important contributor to mechanisms by which tumor cells can be eliminated.
Antibody therapy with anti-EGFRs (epidermal growth factor receptor) effectively
kills tumor target cells predominantly through ADCC [23]. Further study of anti-EGFR
pairings has shed light on the important contribution CDC provides when also elicited by
therapy. The potency of the complement killing system has been shown using a
combination of Cetuximab and Matuzumab, directed toward unique epitopes of EGFR
[23]. This combination approach was capable of activating complement as demonstrated
by C 1q and C4b deposition detected on tumor cells and enhanced killing of human
squamous and glioblastoma cancer cells via CDC. Effective CDC even occurred in dual
anti-EGFR therapy despite high expression of CRPs by these tumor cells [23].
As previously eluded, there are many complement cascade activating and
regulatory proteins with the potential to effect the development of cancer. Several
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complement proteins have been identified as playing a role in cancer elimination. Clq
was found to be responsible for activating the tumor suppressor gene, WaXl, in vitro in
human prostate cancer cells, DU145, enhancing cancer cell apoptosis [21]. Additionally
an anti-tumor agent, the small peptide, tachyplesin was determined to interact with Clq
and thereby activate the classical pathway of complement resulting in the cleavage of C3
and C4 and assembly of the MAC on tumor cells [22]. When TSU tumor cells, another
prostate cancer line, were treated with tachyplesin in the presence or absence of serum,
death in TSU cells was significantly greater in the presence of serum [22]. TSU cells
were targeted for destruction by MAC formation as evident by the fact that cultures were
positive for C4b, C3b, and C5b-9 by ELISA [22].
The above evidence illustrates the importance of complement activation in the
anti-tumor response. Complement as an immune target is favorable for two important
reasons: the components of the complement system are soluble, as opposed to cells and
can more easily access the tumor and secondly, complement proteins can be made highly
available as activation is generated locally and key proteins are made by cells in the
environment [30]. Tumor cell expression of membrane and soluble CRPs inhibiting
complement has been observed in the setting of antibody therapy renders the developing
cancer greater resistance to CDC [6,29]. The expression of CRPs has been demonstrated
to be upregulated by many types of human tumor cells also indicating activation of
complement within the tumor has potential anti-tumor effects, as the tumor develops
complement evasive mechanisms [6,20,31].

In a study of non-small cell lung carcinoma patients, despite Her2/neu
overexpression by the tumor cells, administration of anti-Her2/neu antibody provided
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only 15% therapeutic efficacy as a result of decreased CDC due to tumor cell CD55 and
CD59 expression [30]. In studies involving treatment of NHL patients, expression of
CRPs was related to disease severity and response to rituximab therapy; therapy nonresponsive patients expressed higher levels of CD46 and CD59, and patients with bulky
disease expressed high levels of CD55 and CD59 [24, 32]. Immunohistological studies on
5 types of human carcinomas indicated that expression of CRPs is widely enlisted by
tumors to inhibit complement functions [6]. Additionally tumor stromal cells stained
heavily for CD55 and CD59 CRPs, without positive cells occurring in the adjacent
normal tissues, suggesting the tumors release a soluble form of these regulatory proteins
[6]. These clinical examples illustrate complement activation is critical in the tumor
microenvironment for tumor cell destruction and optimal treatment efficacy. Adaptation
of tumor cells to limit complement within the microenvironment indicates inhibiting
CRPs or directing complement components to the tumor may have anti-tumor potential.

C5a in Cancer:
Translational research efforts support a positive role for C5a in treatment
protocols necessary to the anti-tumor response.

~-glucan

adjuvant therapy significantly

improves monoclonal anti-tumor antibody therapy against tumor growth.

~-glucan,

a

polysaccharide isolated from yeast cell wall, has been demonstrated to prime complement
receptor 3 (CR3) on neutrophils for enhanced tumor killing. Complement activation
during this therapy is critical for efficacy, as it leads to the release of C5a, which is
responsible for recruiting

~-glucan

primed neutrophils [33]. Expression of CD55 by the

human ovarian cancer cell line, SKOV-3, in vivo renders the tumor capable of

10

eliminating therapeutic efficacy of ~-glucan/ HER2/neu antibody combination treatment
by inhibiting C5a release [20]. Additionally, in vitro studies involving human breast
cancer cells demonstrated improvement in tumor cell killing by neutrophils following
treatment of cells with anti-HER2/neu monoclonal antibody fused to either C5a or C5a

desArg [4, 34]. The fusion antibodies were also able to recruit more neutrophils in vitro
and were effective in tumor cell killing at doses at which the standard HER2/neu
antibody shows no effect on tumor cells [4].
Previously, two groups reported on the effect of complement component C5a in
the tumor microenvironment revealing conflicting roles. In 2005, Kim et al. reported C5a
produced by distinct clones of EMT6 (murine mammary sarcoma) cells transfected with
mouse C5a expressing plasmid had a significant effect on tumor growth in vivo. EMT6
C5a clones producing projected low levels of C5a, capable of inducing minor migration
of J774 macrophage cells in vitro, resulted in the most substantial reduction in tumor
growth and regression as compared to control EMT6 cells or EMT6 C5a clones that
induced abundant 1774 cells to migrate [35]. The group reported C5a expressing tumors
showed significant increase in the number of apoptotic cells at various time points post
tumor development, and cell cycle progression was inhibited at all phases. Additionally,
C5a tumor bearing mice experiencing complete tumor regression resisted tumor growth
upon re-challenge [35]. However, no clear immunological or alternative mechanism
mediated by C5a which attributes to this limited tumor growth was defined.
Contrary to these findings. in 2008, the Lambris group demonstrated a protumorigenic role of C5a generated via the classical pathway within the tumor
microenvironment. In this TC-l murine cervical cancer model, C5a was shown to recruit
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significantly more myeloid-derived suppressor cells (MDSCs) of the granulocytic subset
into the tumor [36]. C5a also enhanced the production of immunosuppressive factors,
ROS and RNS (reactive oxygen or nitrogen species), by the monocytic subset ofMDSCs
resulting in the effective inhibition of the anti-tumor specific CD8 T cell response and
increased tumor burden [36]. C5aR deficient mouse tumors showed significantly more
CD8 T cells throughout the tumor, and depletion of these cells eliminated the tumor
growth disparity between the WT and C5aR lacking mice [36].
C5a release and activation of C5aR expressing cells produces many of the
important events of inflammation used by tumors: contraction of smooth muscle and
vasodilation enhancing blood flow to the location resulting in edema and the migration of
neutrophils and macrophages into the site [3, 5, 37]. Additional valuable conditions of
inflammation on tumor growth include ischemia and new blood vessel formation for
delivery of additional nutrients and cells which C5a does not directly contribute [8, 12,
14]. However, the effects of C5a have apparent pro-tumorigenic effects and have been
shown to be responsible for tumor progression in a single model [36]. On the other hand,
as a potent immune modulator in acute inflammation, as well as demonstrating a role, yet
undefined, in tumor regression [35], C5a may prove an effective and necessary
component of the complement system in tumor destruction.

Innate immune cells in cancer:
Innate immune cells including neutrophils, macrophages, natural killer (NK) cells
and dendritic cells are well known for their role in mounting the initial immune attack
after recognition of pathogens during infection, as well as repairing and restoring host
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tissue following the resolution of the infection, but they are capable of more. Innate
immune cells also contribute in the immune surveillance of a host to inhibit the survival
of cancerous cells during tumor development [8, 12]. As evident by studies
demonstrating an increased occurrence and burden of spontaneous and carcinogeninduced tumors developing in mice depleted of NK cells and monocytes/macrophages, or
deficient in perforin, TNF-related apoptosis induced ligand (TRAIL), or GM-CSF [8, 10,
17,38]. Not only are innate immune cells critical to the elimination of cancer cells early
in tumor development, but also in controlling and limiting the duration of the
inflammatory response, as chronic inflammation has been linked to cancer development
[9, 12].
Studies by Hicks et al. with spontaneous regression/complete resistance (SRlCR)
mice clearly showed critical importance of an anti-tumor innate immune cell response.
The group demonstrated a strain of mice resistant to tumor growth or disease
development. The existence of innate immune cell rosettes forming around cancer cells
were responsible for eliminating tumor cells, and this anti-tumor response was
transferable to and long lasting in non-resistant, wild-type mice following the adoptive
transfer of innate immune cell subsets from SRICR mice [39]. It has also been shown
innate immune cells are important in the efficacy of combination anti-tumor therapy
consisting of ~-glucan and a monoclonal antibody. The effect of this treatment is
mediated by neutrophils demonstrated by depletion experiments eliminating neutrophils
effectively eliminates all therapeutic efficacy [33, 40). Another study using rituximab
also revealed the importance of innate immune cell involvement in antibody mediated
therapy and tumor eradication, proposing that rituximab leads to the activation of
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complement resulting in subsequent release of innate immune cell recruiting chemokines
(CCL3 and CCL4) [27]. Depletion studies by this group demonstrated each subset of
innate immune cells; neutrophils, macrophages, or NK cells; showed each played a
critical role in tumor eradication in rituximab treatment.
Antibodies bound to tumor surface antigens trigger the activation of
immunoglobulin G fragment C receptors (Fcyreceptors) expressed predominantly by
innate immune cells initiating a retrograde signaling cascade resulting in cytokine release,
oxidative burst, increased phagocytosis, and more potent ADCC by the receiving cell
[41-43]. Drozitumab, a human monoclonal antibody to death receptor 5 (DR5), and
rituximab have been shown to require signaling through Fcy receptors in order to be
effective in anti-tumor therapy [41]. Binding of the Fcy receptors on tumor infiltrating
innate immune cells from Rag2 knockout mice to drozitumab decorated tumor cells lead
to engagement with drozitumab and DR5, resulting in tumor cell apoptosis [41]. Fey
receptors on innate immune cells are found to be targeted in anti-tumor therapy resulting
in cytotoxic activity by innate immune cells elicited against the tumor.
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CHAPTER 3
OVARIAN CARCINOMA AND A RELEVANT MODEL SYSTEM FOR
TARGETING C5A AND INNATE IMMUNE CELLS FOR IMPROVEMENT OF
IMMUNOTHERAPY AGAINST TUMORS

Ovarian carcinoma:
Epithelial ovarian cancer is diagnosed at a rate of approximately 205,000 cases
per year world wide. More than 13,000 women die with ovarian cancer annually in the
United States, making it the most lethal gynecologic cancer nationally (American Cancer
Society). Due to the overall lack in diagnostic markers, most ovarian cancer patients are
not diagnosed until metastatic stage, with a 5 year overall survival rate of 30-40% [44].
Standard treatment of care following diagnosis of ovarian carcinoma consists of surgical
debulking followed by chemotherapy [44]. In ovarian carcinoma as in other types,
significant research has shown an important immune component including tumor
infiltrating populations of highly immune suppressive cells (including MDSCs and
regulatory T cells) that inhibit anti-tumor immune cell activity, as well as produce factors
that promote the tumor [14, 45]. Strong immunosuppressive and tumor promoting
environments established in ovarian cancer patients lend to the complications in treating
tumors by a single modality without addressing the tumor immune component.
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Necessity of this research:

Activation of the complement cascade affects the local environment, cell
recruitment, cell activation and has profound effects on host outcome. Complement
proteins are capable of initiating and sustaining ari immune response. C5a, in particular,
is an incredibly potent mediator of immune cells through its chemotactic and activation
functions. Targeting a key component of the immune system, such as C5a, in order to
destroy tumor is critical for successful therapy combating tumor progression mechanisms
of limiting immune cell infiltration [10, 20] and stimulation [10, 46], as well as inhibition
of CDC in treatment protocols [7, 24]. Study of the role of C5a in the tumor
microenvironment may demonstrate a method by which to circumvent the limitations
CRPs have on the complement cascade since these have been observed to be upregulated
on many human tumors [6,24,25,29]. Subsequently, the limitations tumors have on
immune cell recruitment and activation locally may be reversed through C5a activity.
C5a can have far-reaching immunological effects by influencing each immune
cell type; however, due to the conflicting published accounts and the breadth of C5a
activity, we feel it is important to address the effect of C5a in a limited system.
lmmunocompromised SCID model use allowed for dissecting the resultant immune
response C5a triggers in the tumor and host by the innate immune cells, exclusively.
Additionally, the tumor cell line of choice, SKOV-3 human ovarian adenocarcinoma cells
are highly aggressive [47] and express abundant surface CD55 [20]. A reduction in
growth of this tumor by the addition of C5a would prove encouraging. The direct
incorporation of C5a into the tumor microenvironment also circumvents the need for
antibodies directed toward CD55. Given that this antigen is expressed on nearly all
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normal cells of the body, elimination of blockade treatment will ensure no damage to
healthy tissue.
Harnessing the potent chemotactic property of C5a may enhance innate immune
cell migration into the tumor. Once cells infiltrate, activation via C5a may foster an
immune stimulating microenvironment, generating proinflammatory innate immune cells
that will produce anti-tumor factors and act as superior effector cells affording adaptive
immune cell benefits in entry and anti-tumor responses. These are all potential results of
introducing C5a in the tumor due to its potent immune response initiating characteristics.
Previously performed studies involving C5a in the tumor microenvironment in vivo
reveal the role of this potent immune mediator is as of yet inconclusive.
It is hypothesized the potent innate immune cell chemoattractant, C5a, expressed

from the tumor microenvironment can alter immune cell infiltration into the tumor by
promoting recruitment of innate immune cells, changing the infiltrating cell milieu and
potentially the phenotype and activity of these cells to destroy tumor cells.
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CHAPTER 4
MATERIALS AND METHODS

scm mice and implantable tumor cell:
All mice used in the in vivo tumor growth studies were treated in agreement with
the established laws and guidelines of the institution. Protocols for tumor studies in mice
were approved by the Institutional Animal Care and Use Committee of the University of
Louisville. Tumor growth studies were performed on mice 6-10 weeks of age. Severe
Combined Immunodeficient (ICR SCID) mice were purchased from Taconic Farms
(Germantown, NY, USA) or Harlan Laboratories (Fox Chase Cancer Center,
Philadelphia, PN, USA). SKOV-3 tumor cells are a human ovarian adenocarcinoma cell
line that express HER-2/neu antigen acquired from the American Tissue Type Collection
(ATCC, Manassass, VA, USA). SKOV-3 cells were injected subcutaneously (s.c.) at a
dose of 7 -lax 106 cells per SCID mouse with BD matrigel matrix basement membrane
(BD Biosciences, Bedford, MA, USA).

In vitro tissue culture:
All cell lines used were cultured at 37°C in a humidified incubator with 5% C02.
Each cell line was cultured in specific growth medium. Media supplements used for cell
culture were obtained from the following vendors: fetal bovine serum (PBS; Atlanta
Biologicals, Lawrenceville, GA, USA); 200 mM L-glutamine (L-gln), antibiotic-
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antimycotic solution (10,000 IV/ml penicillin, 10,000 uglml streptomycin, 25 uglml
amphotericin B), Geneticin, G418 Sulfate all fr<?m Cellgro Mediatech, Inc. (Manassas
V A, USA). SKOV -3 cells and isolated white blood cells when used for cytotoxicity
studies were cultured in McCoys 5A (Caisson Laboratories; North Logan, UT, USA or
MIDSCI; St. Louis, MO, USA) supplemented with 10% FBS, 1% L-gln, and 1%
antibiotic-antimycotic solution. Transfected SKOV-3 cell lines were cultured in the same
media with the addition of 600 uglml geneticin. 1774 murine macrophage cells were
grown in DMEM with 4.5 gIL glucose supplemented with 10% FBS, 1% L-gln, and 1%
antibiotic-antimycotic solution. RPMI with L-gln (Cellgro Mediatech, Inc.) was
supplemented with 5% FBS, DNAse I, collegenase from Clostridium histolyticum, and
hyaluronidase from sheep testes (Sigma, St. Louis, MO, USA) to produce the lOX tumor
lysis buffer for single cell tumor suspension preparation. Yac-l luciferase expressing
cells were generously provided by Dr. Zhang at University of Louisville, Brown Cancer
Center. These cells were cultured in RPMI supplemented with 10% FBS, 1% L-gln, and
1% antibiotic-antimycotic solution.

Generation of C5a expressing tumor cell line:
SKOV -3 WT cells were transfected with murine C5a secreting and empty vector
DNA plasmids generously provided by Dr. Fangting Liang at the Veterinary School of
Medicine at Louisiana State University. Cells were seeded at 9xlO"5 cells per well in a 6well plate the night before the transfection in McCoy's 5A media supplemented with
10% FBS and 1% L-glutamine. The following day, wells 70-80% confluent were
transfected using the Lipofectamine reagent (Invitrogen, Carlsbad, CA, 18324-012)
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protocol. Each well was washed twice with IX PBS prior to the addition of the
LipofectaminelDNA plasmid complexes. After overnight incubation, the transfection
complexes were removed and fresh media was added to the wells. After 2-3 days of cell
growth, selection media containing 600 ug/mL geneticin was added over transfected
cells. Once all cells in the controllLipofectamine only wells had died, supernatants of
confluent transfected cell wells were screened by C5a ELISA (BD Pharmingen, Sparks
MD), and a limiting dilution assay was performed in a 96-well format with the cells from
positive wells. Following the growth of single colonies from the limiting dilution wells,
supernatants of single clones were screened by C5a ELISA. Positive clones were
expanded in T25 flasks, supernatants were screened once cells reached confluency and
cells were injected s.c. into the mammary fat pads of ICR scm mice.
After tumors had developed to 5-6 mm in diameter, tumors were excised and half
of the tumor was pulverized in growth medium. Large tumor pieces were removed and
the cell suspension was washed and suspended in selection media and seeded into a 6well plate. Culture media was changed as necessary, and supernatants over confluent
wells were screened for C5a by ELISA for expression maintenance. The other half of the
tumor was frozen, sectioned, and immunohistochemistry staining with mouse anti-C5a
antibody (BD Pharmingen) was performed. Following in vivo passage, the SKOV-3 C5a
tumor cell clone positive by both ELISA and IRC staining, was expanded and frozen
down for all experiments in this study.
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C5aELISA:
Nunc-Immuno BreakApart and LockWell MaxiSorp wells (VWR International,
LLC, Batavia, IL) were coated with

2~glml

purified rat anti-mouse C5a monoclonal

antibody (BD Pharmingen, 558027) diluted in ELISA coating buffer with pH of 9.35 and
incubated overnight at 4°C. The following day, the coated plate was washed and blocked
with 300 ~l per well of assay diluent for 1-2 hours at room temperature. Cell culture
supernatants over transfected cells were screened undiluted, and the standard curve with
mouse C5a (BD Pharmingen, 622597) was prepared in assay diluent at concentrations
ranging from 55.5 pg to 14.2 nglml. Samples and standards were incubated for 2 hours at
room temperature on a shaker at 200 rpm. After washing the plate, the biotinylated rat
anti-mouse C5a antibody (BD Pharmingen, 558028) was applied at a concentration of
2~glml

in assay diluent and the plate was incubated with rocking at room temperature for

1 hour. Streptavidin-HRP conjugate (BioSource, Invitrogen, 43-4323) was added at
0.65~glml

in assay diluent, and the plate was incubated for 30 minutes at room

temperature on a shaker. Wells were thoroughly washed and TMB Conductivity
Substrate (BioFX Laboratories, Inc., Owings Mills, MD, TMBC-1000-01) that had been
allowed to reach room temperature was added to each well. The plate was left uncovered
and incubated in the dark at room temperature for 10-15 minutes. Following the
colormetric reaction, equal volume stop solution was applied to each well and the
absorbance value at 450 nm was read immediately on a BioRad Model 680 Microplate
Reader using the Microplate Manager 5.2.1 software.
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Immunohistochemistry and immunofluorescence:
Excised tumor samples were divided in half using a scalpel blade, and tumors
were placed with the center of the tumor down into standard size Cryomolds (Tissue Tek,
Sakura Finetek USA, Inc., Torrance CA, 4583) over a thin layer of O.C.T. Compound
(Tissue Tek) freezing media. Tissues were completely covered in O.C.T. and snap frozen
in 2-methylbutane over dry ice. Frozen tumor blocks were kept at -80°C and sections
were cut on a Leica CM 1900 cryostat (Leica), 5mm sections were mounted on
Superfrost Plus microscope slides (Fisher Scientific, Pittsburg, PA, 12-550-15) and stored
at -20°C after drying. Tumor tissue was fixed to the slides in ice cold acetone at room
temperature for 20 minutes. Following fixing, tumor tissue was rehydrated in IX PBS for
5 minutes. A hydrophobic boundary was applied surrounding the tissue on the slide, and
tissue samples were treated with 3% hydrogen peroxide for 30 minutes at room
temperature in a humidity chamber. Slides were rinsed in IX PBS 3 times for 3 minutes
each. Blocking buffer (3% BSA in IX PBS) was applied to the tissue and samples were
blocked at room temperature for 2 hours.
After slides were blocked, buffer was removed by shaking the slide and drying
excess liquid with a kim wipe. Biotin and streptavidin blocking steps were performed
with Vector AvidinlBiotin Blocking Kit (Vector Laboratories, Inc. Burlingame, CA SP2001) using instructions provided with the kit. After rinsing the slides one time in PBS
following each blocking step, biotinylated rat anti-mouse C5a antibody (BD Parmingen
558028) was added to appropriate tissue sections at 2~g1mL diluted in blocking buffer.
Slides were incubated in the humidity chamber overnight at 4°C. After incubation, slides
were washed in IX PBS 3 times for 3 minutes each. Streptavidin-HRP from the Vector
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Peroxidase Substrate Binding Kit AEC (Vector Laboratories, SK-4200) was prepared
according to the kit instructions, applied to each section on the slides, incubated in the
dark for 8-10 minutes for visualization of the areas that bound the biotinylated antibody.
Upon visualization of the colormetric reaction occurring, slides were rinsed in tap water,
and counterstain with hematoxylin was performed.
Tumor tissue slides were prepared with only slight differences for
immunofluorescence staining. Once tumors were sectioned and applied to the slide, the
slides were kept overnight at room temperature and allowed to dry in the fume hood.
Following drying, the slides were fixed in ice cold acetone for 12 minutes. The blocking
step was performed at room temperature for 1-2 hours using a blocking buffer containing
1% BSA, 5% rat serum, and 1:400 dilution anti-CD16/32 Fcyreceptor antibody. Staining
with directly labeled fluorescent antibodies, HMa2 Alexa Fluor 647 (sharing epitope
binding with DX5) ( Biolegend, San Diego, CA, 103511) and F4/80 APC (Biolegend,
123116) , was performed at 1:50 dilution for 45 minutes at 37°C in a humidity chamber
with appropriate isotype controls conducted in parallel. The appropriate isotype controls
were performed simultaneously on similar tissue sections with Armenian hamster IgG
isotype Alexa Fluor 647 (Biolegend 400924) and Rat IgG2a isotype APC (Biolegend,
400511). Slides were washed and then a DAPI (Invitrogen, D3571) stain was added to
each section for 30 sec-l min.

In vitro cell growth kinetics:
Wild-type and transfected SKOV-3 cell (SKOV-3 WT, SKOV-3 C5a and control
vector (CV)) growth was measured in vitro, in real-time, using the ACEA system which
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measures cell attachment to the culture plate surface containing a conductor allowing for
detection of the impedance of electrical current upon adherence (Acea Biosciences, Inc.;
San Diego, CA, USA). Each cell line was plated in quadruplicate, in the Acea 96 well
plate format, at 5 x 103 cells per well. Cells were incubated at 37°C in a humidified 5%
C02 incubator for 40 hours. Cell indices read out based on the number of cells attached to
the bottom of the plate well was used to calculate the growth of each cell line over the
course of time. The Acea assay system reports cell index, a value calculated by
measuring impedance of electrical current on the well bottom which occurs when cells in
culture adhere to the surface.

In vitro cytotoxicity:
During cytotoxicity experiments utilizing the Acea system, SKOV -3 WT cells
were plated and allowed to adhere and grow for about 24 hours, until reaching a cell
index of 1-1.6. Several innate immune cell populations were used in various cytotoxicity
experiments all purified from SCID mice. NaYve mice spleens were used in preparation of
innate immune leukocytes. Following single cell suspension and red blood lysis
treatment, splenocytes were added to a T75 flask in medium for 45 minutes. Nonadherent cells were collected for cytotoxicity studies, and the white blood cell samples
contained mostly NK cells and neutrophils, excluding adherent macrophages. These
innate immune cells were added at an effector to tumor cell ratio of 20: 1.
Gr-l+CDllb+ cells sorted from SKOV-3 C5a and SKOV-3 CV tumors following
in vivo growth were added to wells containing the growing SKOV-3 WT cells in the
presence or absence of SCID mouse white blood cells isolated from the spleen as
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described previously. The Gr-1 +CD11b+ sorted tumor infiltrating cells were added at a
ratio of 2: 1. Tumor and effector cells were co-incubated overnight, and SKOV -3 WT cell
cytotoxicity was calculated at 28 hours. NK cells were purified and pooled from naive
SCID spleens using the EasySep magnetic beads kit for positive selection of DXS+ cells
(StemCell Technologies, British Columbia, Canada, 187SS). Purity of NK cells used for
cytotoxicity assays was analyzed by flow cytometry and was found to be around 80%,
with red blood cells again being the predominant contaminant. Recombinant mouse CSa
protein (R&D systems, Minneapolis, MN, 21S0-CS/CF) was diluted in medium and
added to the wells to determine levels of CSa that may enhance macrophage and/or NK
cell cytotoxicity of tumor cells.
In the Yac-1 cytotoxicity assay, Yac-1 cells transfected to express luciferase were
utilized to identify if the addition of CSa could enhance NK cell specific killing of tumor
cells. Yac-1 Luciferase (Luc) cells were plated in a 96-well plate at 2x 104 per well.
Positive control wells included only Yac-1 cells and negative control wells had added
Triton X at 1%. Experimental wells included purified NK cells prepared as mentioned
above at a ratio to the Yac-1 Luc cells of 1: 1 with or without the addition of recombinant
mouse CSa in decreasing concentrations and IL-2 cytokine (R&D systems, 11S0-MUCF)
was added to each well at 100nglmL. Tumor cells and NK cells were co-cultured for 6
and 12 hours, following which cells were lysed and combined with Luciferase enzyme
assay reagent (Promega, Madison, WI, E1S00) and luminescence released by live Yac-1
Luc in each well was collected as a reading of relative light units. Each condition was
performed with 3-6 replicates.
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In vitro chemotaxis assay:
SKOV-3 CV and C5a cells were each cultured in a T25 flask to 90% confluency
and fresh media was applied to the cells. Flasks were returned to the 37°C incubator with
humidity and 5% CO2 for 16-18 hours. Supernatant was collected from each flask and
debris and cells were pelleted at 1500 rpm for 5 minutes. The supernatant, approximately
5 ml, was then transferred to the sample reservoir of a Centriprep Ultracel YM-3
(Millipore, Billerica, MA, 4303) unit for concentrating the C5a produced by the cells.
The YM-3 was spun at 3000 x g in a Sorvall RC-3B refrigerated centrifuge for 2 hours.
After centrifugation, the filtrate was collected in a 15 ml conical and the retentate,
approximately 1 ml, containing the C5a was collected and stored at 4°C until the
chemotaxis assay the following day. 1774 murine macrophage cell line (ATCC,
Manassas, VA) was used as responder cells in the chemotaxis assay. Concentrated
supernatants were added to the bottom well of a HTS Transwe1l96 well plate with 5.01lm
Polycarbonate Membranes (Coming, Coming, NY), and 1774 cells were added to the
upper chamber of the transwell plate at Ix 10"5 cells per well. The plate was incubated at
37°C for 3 hours before the 1774 murine macrophage cells that were chemoattracted to
the bottom well were collected and counted. Migrated cells were collected from the wells
and counted by trypan exclusion. Each concentrated media condition was plated in
triplicate for the chemotaxis assay.

Flow cytometry and cell sorting:
Single cell suspensions of each tissue or blood sample were prepared before
antibody staining was performed. Briefly, peripheral blood was acquired from mice
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through retro-orbital bleeding and collected in heparin, ACK lysis was performed twice
for S then 3 minutes, cells were washed and resuspended in 100~1 of IX PBS and placed
on ice. Spleen samples were processed into a single cell suspension using the end of a
syringe plunger in a filter, washed, and pelleted. Cells were re-filtered, ACK lysis was
performed one time for 30 seconds, cells were then counted and put on ice. Excised
tumor masses were minced with a scalpel blade and transferred to a ISml conical tube in
a total of lOmls of IX tumor lysis buffer in supplemented McCoys SA media. Tumor
samples were digested in lysis buffer for 4S minutes with continuous rotation at 37°C.
Following digestion, larger tumor pieces were allowed to settle, the supernatants were
transferred to a new tube, and cells pelleted by centrifugation. Tumor cell pellets were
resuspended, filtered, and pelleted, then cells were counted and placed on ice.
Staining protocols for surface markers on the prepared single cell suspensions
were performed on ice beginning with incubation with anti-CDI6/32 Fcyreceptor
antibody for IS minutes. Gr-l-PE CyS.S and CDllb-APC were used to identify
neutrophils, F4/80-PE and CDllb-APC were used to identify macrophages, and DXSAPC and CD 11 b-PECyS.S were used to identify NK cells. Antibody combinations were
added to appropriate tubes of cells following the blocking step; tubes remained on ice for
staining for 20 minutes, followed by washes with IX PBS. All antibodies were purchased
from Biolegend with the exception of the blocking antibody which was prepared from
hybridoma culture in the lab. Stained samples were collected on FACS Calibur following
analysis of collected events using FloJo software.
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Quantitative RT -peR:
Small portions of excised tumors were removed with a scalpel blade and weighed.
The tumor pieces were placed in tubes containing 1 mL of Trizol reagent (Invitrogen) and
kept at -80°C for less than two weeks before RNA extraction. Samples were thawed on
ice, then each sample was placed in a small culture dish and processed individually by
pressing flat and breaking up the tumor with the back end of a 3 mL syringe plunger until
many small pieces were generated. Then all Trizol and tumor pieces were pipetted back
into the tube and samples were vortexed briefly. While processing tumor tissue for
extraction, samples were kept on ice. Following sample preparation, samples were placed
in a rack at room temperature for 5 minutes. Then 200 JlL of chloroform was added to
each tube followed by manual, vigorous shaking of the samples for 15 seconds, and
another 2 minute incubation at room temperature. Samples were then spun at 4°C for 15
minutes at 12,000 x g and the top aqueous layer was carefully removed and pipetted into
a clean tube. Isopropanol was added at a volume of 500 JlL in order to precipitate the
RNA, tubes were capped and inverted 3-4 times to mix well and incubated at room
temperature for 10 minutes. The same spin as above was performed on samples with the
exception of lasting 10 minutes. The isopropanol supernatant was removed and pellets of
RNA were washed with 75% ethanol and vortexed followed by a final spin at 4°C for 5
minutes at 7,500 x g. Supernatants were removed and pellets were dried for 10 minutes
on the bench top before resuspended in small volume of RNase free water. RNA samples
were quantitated immediately utilizing the quantifying program. Reverse transcription
(BioRad) reactions were performed using 1 Jlg of each RNA sample and the cDNA
generated was used for all subsequent qRT-PCR gene expression reactions.
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Cytospin and stain:
Cells remaining following sort for tumor infiltrating Gr-l +CD 11 b+ and CD 11 b+
cells for cytotoxicity assay were applied at 100 JlL with a pipette to the Shandon premade cuvettes (Shandon Inc, Pittsburg, PA) with slide inserted. Only a small number of
cells were used for visualization. Cells were spun in Shandon Cytospin 3 centrifuge at
100 rpm for 2 minutes. After spinning, the slide was allowed to air dry, cells were fixed
to the slide with methanol, and then allowed to completely air dry again before staining.
Protocol Hema 3 solution I and II (Fisher Diagnostics, Middletown, VA) were used for
cell visualization. Slides were submerged in solution I for 30 seconds followed by water
then solution II for 1 minute. Slides were rinsed in water, dried and a cover slip was
applied. Cells analyzed by microscopy under 20X and 40X magnification. Images were
captured using the Nikon Eclipse E400.

Graphing and statistical analysis:
Prism 4.0 (GraphPad Software: San Diego, CA, USA) was utilized in creating
graphs and analyzing data collected from in vitro and in vivo studies. Following C5a
ELISA the standard curve was graphed, linear regression test performed, and sample
concentrations were extrapolated from the standard curve. Analysis of tumor growth
significance and significance between the percentages of infiltrating cells following flow
utilized the Student's t test. The survival curves were generated using the Kaplan-Meier
method and the log rand test was used to analyze significance between the curves
representing two groups. The correlation between cell infiltrates and tumor weight was
analyzed using Pearson's correlation. For the Yac-l Luc cytotoxicity assays, specific
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cytotoxicity was calculated using the read out values by the following equation: relative
light units of experimental well/average relative light units of positive control
wells=cytotoxicity, (I-cytotoxicity) x 100=% specific lysis.
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CHAPTER 5
C5A EXPRESSION FROM SKOV-3 CELLS

Expression of functionally active mouse complement component C5a from SKOV-3
human tumor cell line
The human ovarian adenocarcinoma cell line, SKOV -3, has been shown to
express the CRP CD55 which demonstrated a significant role in reducing therapeutic
efficacy of ~-glucanlanti-HER-2/neu combination treatment [20]. CD55 accelerated
inhibition of C5a release resulted in diminished tumor infiltration of ~-glucan primed
neutrophils [20]. SKOV -3 cells were selected for the transfection of mouse C5a to
determine if C5a expression and the chemotactic effects of C5a from the tumor could
enhance the recruitment of leukocytes to the tumor microenvironment, eliminating the
negative effects of CD55.
The double stranded DNA construct used encoded for mouse C5a (secreted) and
geneticin resistance for selection of positively transfected clones. Prior to transfection of
SKOV-3 wild-type (WT) cells, a kill assay was performed in which the geneticin 0418
concentration appropriate for killing all living SKOV -3 WT cells in no less than a weeks
time was determined: 600 ugimL. In addition to survival in selective media by transfected
cells, ELISA was used for detection of C5a released into the supernatants, and SKOV-3
WT cells were confirmed not to express C5a (Table 1). Identification of C5a positive
cells from the originally transfected cells that grew out of selection was followed by a
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limiting dilution assay to isolate single clones that expressed substantial levels of C5a by
ELISA (Table 2,3). Selected clones were expanded for injection and screened by ELISA
prior to in vivo passage in SCID mice.
Table 1.
sample ID

absorbance ng/mLC5a
0.1425

-0.288

blank

0.137

-0.2982

SKOV-3 WT

0.1345

-0.3029

LLC

0.1735

0.02734

7

0.184

0.05469

6

0.251

0.10938

5

0.339

0.21875

4

0.633

0.4375

3

1.043

0.875

2

1.563

1.75

1

Table 1: C5a ELISA of SKOV-3 WT cells and standard control samples 1-7. LLC
(Lewis Lung Carcinoma) cell supernatant screened as tumor sample negative control.
Table 2.
absorbance
0.148
0.92
0.276
0.947
0.281
0.399
0.252
2.805
0.137
0.261
0.237
0.232

ng/mL C5a
0.085644
1.150966
0.2482458
1.188813
0.2552545
0.4206598
0.2146041
3.793246
0.053404
0.2272197
0.193578
0.1865693

sample ID
Blank
1B6
1D11
1ClO
2B6
3D8
5B6
2B5
1G8
4C7
1DlO
1F2

absorbance
0.12
0.167
0.498
0.174
0.136
0.188
0.157
0.337

ng/mLC5a
0.0600549
0.132585
0.6433822
0.1433873
0.084746
0.164992
0.117153
0.394928

sample ID
Blank
2B4
1B2
1F5
IE 7
1B7
2D2
1C8

Table 2: C5a ELISA for SKOV -3 C5a transfected clones. Clones from the limiting
dilution assay 96 well plates were screened once wells reached confluency. Cells from
positive wells were collected, expanded, and re-screened in preparation for subcutaneous
injection, or in vivo passage. In vivo growth of the chosen clone was critical to the
establishment of a SKOV-3 C5a expressing cell line.
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Table 3
sample ID

absorbance ng/mLCSa

-0.OS63
0.14101
-0. lOS 3
0.97S9S
-0.1277

0. 182
0.367
0.136

LI S
O. 11S

blank
lB6
lClO

2BS
lB8

Table 3: CSa ELISA screen of SKOV-3 CSa supernatants from cells used for in vivo
passage: Re-screen of su~ernatant of expanded cells injected s.c. in individual SCID mice
for in vivo passage (lxlO or greater cells). Screening results demonstrate variations in
CSa concentrations contained in cell supernatants during culture. lClO previously had
high concentrations of CSa, and following in vivo passage the 1C 10 clone was selected as
a result of high concentration of CSa produced in culture supernatants and positive
staining by mc. Lack of detection ofCSa in the supernatant of the lClO SKOV-3 CSa
clone demonstrates the expression of CSa may be transient, or kinetics of CSa secretion
may vary following transfection. This creates some difficulty in quantifying the CSa
production by cells.
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Figure 1: SKOV-3 CSa transfected clones maintain CSa secretion following in vivo
passage. Screening of culture supernatant for CSa by ELISA revealed CSa production
could be detected from clones following growth in vivo. 824 lClO was the SKOV-3 CSa
transfected clone selected for all subsequent in vivo and in vitro experiments due to the
highest expression levels of CSa following in vivo passage. (In addition, it was the only
tumor sample following in vivo passage in which CSa staining was observed abundantly
in mc experiments.) SKOV-3 CSa is 824 lClO clone passaged in vivo.
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Table 4.
absorbance ng/mLC5a
0.10101
0.178

absorbance nglmLC5a sample ID
0.0453 823 10/24-28
0.081

sample ID
821 10/15

0.204

0.11619

82310/24

0.071

0.03967

82410124

0.108

82110124

822 10124-28

82210/15

0.178
0.176

0.10101

0.12

0.06067
0.06751

0.105

0.05896

82410/15

0.848

0.09984
0.53492

466910/28
824 10/24-28

0.081

0.0453

823 10/15

0.159

0.08997

1963 10128

0.118
0.113

0.06637

2B51O/15
821 10124-28

0.203

0.11561

2B5

0.581
0.162

0.35085
0.0917

4669

0.273

0.15715

1963

0.086

0.04899

Blank

0.738

0.06352
0.45715

0.268

0.15416

0.13

0.07324

1963 10124
2B510124

0.125
0.114

0.01756

blank

0.141

0.118
0.115

-0.0298
-0.0126
-0.0255

82424hr
82451hr

0.106
0.128
0.139

0.142
0.302

0.09068
0.77889

82472hr
824 inj d6

0.308
0.131
0.395
0.132
0.134

2B5 10124-28

822

0.08638
-0.0642

822d4

0.03046
0.07777

82324hr
82372hr

0.24122

82351hr

2B527hr

0.177
0.161

0.1724

823 d6

0.8047

2B548hr

0.152

466924hr

0.04336

2B5 d5

0.154

0.13369
0.14229

1.17891

2B5 d7
82124hr

0.195

0.31865

466975hr

0.157

0.1552

196324hr

82148hr

0.218
0.155
0.125

0.41758
0.1466

196351hr
196316hr

0.01756

466916hr
82116hr

0.04767

0.124

0.05627
0.01326

0.092

-0.1244

0.128
0.12

0.03046
-0.004

0.18
0.169

82175hr
821 d6
821 d4

0.142

0.25413

821 d9
82224hr

0.104
0.105

0.09068
-0.0728
-0.0685

0.20681

82248hr

0.126

0.02186

822d9

466948hr

82216hr
82316hr
82416hr

Table 4: Time course for optlIruzatlOn of the detectIon of C5a by ELISA of cell lInes
following in vivo passage. Positive clones that had been successfully passaged in vivo
were grown in vitro and supernatant from these cells was collected at various time points
following plating. Clones revealed different time points for peak: C5a expression in vitro.
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Table 5.
absorbance ng/mLc5a
0.261

samJ>Je ID
1.140633 SKOV-3 C5a 1

0.165

0.323909

SKOV-3 CV

0.217

0.766301

SKOV-3 C5a2

Table 5: C5a ELISA of SKOV-3 C5a (824 1ClO) and CV. Both cell lines had been
passaged in vivo and were screened for production of C5a by ELISA prior to using the
cells in experiments. C5a production maintenance throughout culturing and experiments
was routinely screened. Sample SKOV-3 C5a 1: 2 days culture in T25 flask. Sample
SKOV-3 C5a 2: 4 days culture in T25 flask. Variation in C5a concentration was observed
in samples acquired over the same cells at different times.

Table 6.
absorbance ng/mLC5a

sample ID

0.296

0.63

lClO

0.318

0.7

1C8

0.244

0.46

1Dll

0.199

0.32

IB2

0.328

0.73

2B6

0.516

1.33

2B5

0.327

0.73

8241ClO

0.482

1.22

8241ClO

Table 6: C5a production screen of pre-in vivo passage clones frozen down. Re-screen
after cells were frozen revealed maintenance of C5a expression and the SKOV-3 C5a in
vivo passage clone (824 1C 10) was screened prior to use in an experiment.
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Gr-}

CD3}

CDlle

Figure 2: Summary of results for IHC staining of SKOV -3 WT and SKOV -3 C5a.
Following excision of tumors from individual mice, half of the tumor was frozen for
sectioning and staining. Tissues were stained with biotinylated anti-mouse Or-1 antibody,
anti-mouse CD31, and anti-mouse CD11c to analyze if any differences occurred in the
presence of these cell surface markers between tumor types as a result of the expression
of C5a. It was determined by this method that no significant differences between the cell
lines for the infiltration of neutrophils (Or-I) or dendritic cells (CD lIe), or the density of
blood vessels (CD31) was apparent.
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Tumors for in vivo passage mice were monitored and allowed to grow until tumors
reached 5-6 mm diameter. Following excision and culture of in vivo passaged SKOV-3
C5a positive clones, maintenance of C5a expression was confrrmed by performing
ELISA (Fig. 1) on culture supernatants. Of note, it was observed at some time points that
C5a levels were low to undetectable in previously positive clones before and after in vivo
passage (Table 2, 3, 4, 6). However, subsequent ELISA would again confrrm positive
expression. Kinetics of C5a expression based on cell status, phase of growth, or condition
of growth media is critical in the screening process. Following time course experiments,
it was difficult to pinpoint a time post plating at which SKOV-3 C5a cells could be
screened and C5a levels would consistently be detected, further clarifying a transient C5a
expression and complicating C5a quantification. 2B5 clone from before in vivo passage
was utilized as a positive control for these experiments (Table 4). C5a expressing
transfected cells expressed lower ranges of nglmL to pglmL concentrations (1.2 nglmL250 pglmL) (Fig. 4a). Initial screening by IHC comparing SKOV -3 C5a and SKOV-3
WT tumors for infiltration of Gr-l + and CD 11 c+ cells, as well as the presence of CD31 +
cells revealed no significant difference (Fig. 2).
The cells of primary interest in C5aR response were the cells of the innate
immune system. Splenocytes from SCID animals were prepared and stained for flow
cytometric analysis of the general expression of C5aR both extracellularly and
intracellularly (Fig. 3a-c). All cells screened, NK cells; monocytes; neutrophils;
macrophages; and dendritic cells; showed minimal to moderate levels of the receptor
expressed on the surface, and nearly all of each subset screened expressed the C5aR
intracellularly (Fig. 3a-c). In addition, to ensure the C5a expression from SKOV-3 tumor
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cells would not directly affect the growth of the tumor cells, but rather, alterations in
growth would be a result of the receptor ligand interaction on host cells, SKOV -3 WT
cells were also stained for C5aR surface expression (Fig 3d).
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Figure 3: SCID immune and SKOV -3 WT cells expression of C5aR. (a) GrlintCDllb+ (A), Gr-l+CDllb+ (B), (b) CDllc+ (C), F4/80+ (D), (c) DX5+ (A),
DX5+CDllb+ (B), and CDllb+ (C) cell subsets from spleen preparation expression
of extracellular and intracellular C5aR. There is a small shift in all subsets evaluated
revealing a degree of basal level surface expression of C5aR on circulating
leukocytes. Additionally a huge percentage, nearly all cells, express some level of
C5aR inside the cell, which is expected of G-coupled protein receptors. (D) SKOV-3
WT cells from in vitro culture lack C5aR expression.
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SKOV -3 WT tumor cells were also transfected with control vector (CV) plasmid,
lacking C5a expression (Table 5). These cells were prepared in a slightly different way
due to lack of C5a expression. The transfection and initial growth selection process was
identical, but the numerous rounds of screening by ELISA was omitted, as well as the
limiting dilution assay. Once transfected cells grew out of selection following the
transfection, several clones were passaged in vivo and determined to lack C5a expression
by ELISA (Table 5, Fig. 4a,d).
In order to determine the transfection or introduction of C5a expression did not
introduce any growth disparities into the CV or C5a cell lines, in vitro growth kinetics of
all relevant cell lines was monitored in real time using the Acea assay system. Both C5a
and CV transfected clones displayed an initial in vitro growth enhancement over SKOV-3
WT, which was no longer apparent after 12 hours of culture (Fig. 4c); all three cell lines
were determined to grow equally well. In vitro growth studies did not look greater than
40 hours following plating of cells due to restraints in well size; however it may be
important to determine long term in vitro growth similarities. SKOV -3 WT cells seem to
be growing well at 40 hours and at later time points may begin to grow significantly
better than the transfected cell lines. In vivo data presented below suggests otherwise,
since SKOV -3 WT and CV cells grow similarly in vivo up to 38 days (Fig. 5a).
Additionally, to determine the C5a expressed by C5a expressing transfected
SKOV -3 cells following in vivo passage was functionally active, an in vitro chemotaxis
assay was performed using transfected cell culture supernatants that had been
approximately 6 times concentrated by centrifugation. Chemotactic functionality of C5a
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a

b

c
6 hours c:::J
12 hours c:::J
20 hours
30 hours _
40 hours _

SKOV-3 CSa 8241CI0
...

SKOV-3WT

d

absorbance nglmLC5a sampleID
0.0955
0.123
blank
0.141
0.272 SKOV-3 C5a
0.082
0.079 SKOV-3 CV
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Figure 4: SKOV-3 C5a, CV, and WT C5a expression and in vitro characterization of
SKOV-3 cell lines. (a) ELISA assays were performed before experiments using
SKOV-3 C5a (824 lClO) cells or supernatants in vivo or in vitro. Screening, by
ELISA, of supernatants from SKOV-3 C5a, CV, and WT cells throughout the time of
study revealed that levels of C5a expressed by SKOV-3 C5a transfected cell line
varied during culture. The bar graph on the left shows C5a ELISA acquired 4-102009, and the bar graph on the right from 4-27-2010. The SKOV-3 C5a clone selected
for experimental study demonstrated different levels of C5a depending on size of
culture vessel, cell confluency, time in culture, amount of time supernatant had been
applied. (b) Following tumor excision from SCID mice injected with isolated SKOV-3
clones expressing C5a or the CV, one half of the tumor was frozen for sectioning and
analysis of C5a expression by IRC, with rat anti-mouse C5a monoclonal antibody. (c)
Following transfection before monitored for growth differences in vivo, SKOV -3 C5a
and CV cells grown and screened for C5a expression following in vivo passage were
plated to determine the existence of in vitro growth disparities from SKOV -3 WT cells
due to the transfection or the introduction of C5a expression. (d) C5a functional
activity was assessed through chemotactic assays. Overnight culture supernatants,
similar to ELISA samples, were collected from confluent T25 flasks and concentrated
by centrifugation. The migration of J774 murine macrophage cell line from the
transwell to the supernatant (from the samples in the 412712010 ELISA (a» in the
bottom well was quantified by microscope evaluation of trypan blue negative cells
collected from the lower chamber following a three hour incubation.
in the transfected SKOV -3 supernatant was determined by the enhanced migration,
although not significantly, of J774 murine macrophage cell line to the SKOV-3 C5a
transfected cell supernatant (Fig. 4d). The SKOV -3 C5a cell line was successfully
generated following transfection, limiting dilution assay for acquisition of a single clone
generated line, and multiple rounds of ELISA C5a screening with IRC confirmation of
the 824 lClO SKOV-3 C5a clone as the cell line used for study. It must also be
considered that even though the cell culture supernatants were serum free, that some
other agent may have been enhanced in the culture supernatant to affect the chemotaxis
of the J774 cells. For example, exosomes released by tumor cells may have an influence
on migrating cells, and the composition of these exosomes following transfection may be
altered [48].
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SKOV·3 CSa expressing tumor cells have significantly reduced growth in vivo
Using the ICR SCID-immunocompromisedlSKOV-3 tumor model was beneficial
on two fronts. It permitted for focus on the effect of C5a on innate immune cells'
infiltration and functional activity in the tumor, exclusively. Cells of the innate immune
system express abundant C5aR so they were hypothesized to be the main targets. Figure
3 demonstrates that indeed the innate immune cells (Fig. 3a-c) circulating through SCID
mice express both surface and intracellular C5aR while the tumor cells did not (Fig. 3d).
Additionally, this model allowed study of an aggressive human tumor type, SKOV-3
ovarian adenocarcinoma which overexpresses the CRP CD55 [20]. Overexpression of
CD55 ultimately results in accelerated elimination of the C5 convertase, completely
terminating the release of C5a endogenously [7].

scm mice were implanted with 7-10 x 106 of SKOV-3 C5a, SKOV-3 CV, or
SKOV-3 WT cells s.c. Solid tumor growth at the site of injection was monitored and
measured every 2-4 days following development. All tumor cell lines demonstrated
similar initial in vivo growth; however, beginning around day 24 following tumor cell
injection, SKOV-3 C5a tumors revealed significant reduction in tumor progression (Fig.
5a). Tumor development in scm mice bearing SKOV-3 C5a tumors slowed, and these
mice could have survived longer than control tumor-bearing mice which reached the
I2mm diameter endpoint measurement tumor size (Fig 5c) to determine enhanced
survival. However, as required by animal care restrictions, mice bearing tumors with a
diameter of I5mm must be euthanized, and SKOV -3 C5a mice were euthanized for the
purpose of simultaneous study with SKOV-3 CV and WT mice with endpoint tumors.
Upon excision at an endpoint time between 31 and 38 days for three separate
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experiments, C5a expressing tumors weighed significantly less than both CV and WT
tumors (Fig. 5b). At sacrifice, the outward appearance of SKOV-3 CV mice tumors were
necrotic, which was not the case fro the smaller SKOV-3 C5a tumors that showed limited
or no necrosis (Fig. 5d).
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"

SKOV-3 CV Tumors

SKOV-3 C5a Tumors

Figure 5: SKOV-3 C5a in vivo tumor growth is significantly reduced. (a) SCID mice
were injected s.c. with SKOV-3 C5a (n=20), SKOV-3 CV (n=16), or SKOV-3 WT
(n=8) and growth was monitored by measuring and averaging two perpendicular
tumor diameters. Around day 24 post tumor cell injection, SKOV -3 C5a tumors grew
significantly less well. (b) The significance in tumor growth could also be visualized
upon excision when tumors were weighed. (c) Only 2 mice bearing C5a expressing
SKOV-3 tumors reached 12 mm before the endpoint as compared with CV (7) and
WT (5) SKOV-3 tumor bearing mice. (d) Image taken following sacrifice of tumor
bearing mice reveals gross differences in appearance between SKOV-3 C5a (red
arrows) and SKOV-3 CV (blue arrows). The necrotic phenotype was also observed in
mice bearing SKOV -3 WT tumors (not shown).
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CHAPTER 6
EFFECT OF C5A RELEASE FROM SKOV-3 CELLS IMPACTS THE TUMOR
MICROENVIRONMENT GREATLY: INFIL TRATING POPULATIONS AND
RELEASE OF IMMUNE AND GROWTH MEDIATORS

Innate immune cell subsets enhanced inrIItration of SKOV-3 C5a expressing tumors
Cells of the innate immune system have been shown to be important to mount an
anti-tumor response [33, 39, 49], as well as play an important role in sustaining the
immunosuppressive environment and angiogenic switch promoting tumor growth and
metastasis [15,50]. Expression of C5a from the tumor environment may harness the antitumor response of these cells because it potently stimulates these cells expressing C5aR
for a proinflammatory response. However, this potency of C5a as a proinflammatory
peptide and its pronounced role in death following sepsis [3,34,51] requires caution
when utilizing it in vivo as a chemotactic and stimulatory agent. It was important to note
any dramatic systemic effects as a result of the introduction of C5a even from the limited
environment of the tumor of these animals. Tumors were examined for the role of C5a in
enhancing the migration of innate immune cells into the tumor tissue.
NK cells were identified by the expression of DX5 and/or CD 11 b, macrophages
by the expression of F4/80 and/or CD 11 b, and neutrophils by the expression of high
levels of Gr-1 and CD11b. As an additional marker with DX5, CD11b expression by NK
cells has been associated with activation and maturation [52]. Minimal significant
systemic effects were observed in the percentage of circulating innate leukocyte subsets
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in the peripheral blood and spleens aside from an increase in NK cells in both sample
types of C5a tumor-bearing mice (data not shown). Additionally, naIve mouse spleen
samples contained the highest percentage of neutrophils (Gr-l high CD 11 b high),
significantly more than C5a and control tumor bearing mouse spleens (data not shown).
Despite the reduction of neutrophils in C5a tumor bearing mice spleens, significantly
more occurred than in the spleens of CV tumor bearing mice indicating the reduction in
neutrophils was less dramatic with C5a expression.
However, several changes in the percentage of infiltrating innate leukocytes were
observed between SKOV -3 C5a and CV tumors. C5a tumors showed both an increased
percentage in infiltrating DX5+CD 11 b+ NK cells (Fig. 6a) and F4/S0+, F4/S0+CD 11 b+
subsets of macrophages

(Fi~.

6b). Although by flow cytometric analysis there was no

difference in the percentages of Gr-l +CD 11 b+ cells infiltrating the tumor, when
correlated with tumor weight, more Gr-l +CD 11 b+ neutrophils were found to infiltrate
smaller C5a expressing tumors (Fig. 6c). C5a appears to be enhancing the infiltration of
both NK cells and macrophages, two distinct subsets of innate immune cells that have
been shown to be important in tumor immunity [10, 39,49,53,54].
Neutrophils express the most abundant C5aR of all innate immune cells and
should therefore be the most sensitive in responding to C5a release in the tumor [5].
However, there is not evidence that C5a is recruiting more neutrophils to the tumor. The
short-lived cells may be infiltrating the tumor, activated to kill tumor cells, and dying, so
increased percentages of Gr-l +CD 11 b+ cells are not detected at this time point, and the
shorter half-life of these cells results in little accumulation. The heightened sensitivity of
neutrophils to C5a may be the reason a difference in infiltration of these cells is only seen
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when correlated with tumor size which may result directly from the amount of C5a
released in vivo. It is important to note these tumor infiltrating neutrophils were
demonstrated to express C5aR extracellularly (Fig. 6c), despite the presumed continuous
release of C5a into the environment. A previous tumor C5a model demonstrated
infiltrating Gr-l +CD 11 b+ cells only expressed intracellular C5aR [36]. SKOV-3 C5a
tumors have shown enhanced infiltration in two subsets of migrating innate leukocytes,
additionally C5a release may enhance the cytotoxic effector function and/or anti-tumor
phenotype of these cells upon arrival.
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Figure 6: Enhanced infiltration of innate immune cell subsets in SKOV -3 C5a tumors.
When control tumor bearing mice tumor size reached endpoint measurements at 31-38
days post injection, all mice were sacrificed and tumor samples were collected and
processed for staining with innate immune cell surface antigen recognizing antibodies.
Differences in percentages of innate immune cells infiltrating the tumor occurred in both
the (a) DX5+CDllb+ NK cell and (b) F480intCDllb+ and F4/80+CDllb+ macrophage
subsets. No difference was seen between SKOV-3 C5a and CV tumor (c) Gr-l+CDllb+
infiltrate percentages; however, when considering both the percentage of neutrophil
infiltrates and the weight/size of the excised tumor, C5a tumors showed a correlation
between smaller tumor size and greater percentages of Gr-l +CD 11 b+ cells infiltrating.
The SKOV-3 C5a Gr-l +CD 11 b+ and CD 11 b+ infiltrating subsets expressed surface C5aR
to similar levels, despite the C5a released in vivo.
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Tumor microenvironment analysis reveals a significant decrease in the production
of pro-tumorigenic factors
A small portion of tumor sample was cut away following tumor weight
measurement. This portion was processed for quantitative real time-polymerase chain
reaction (qRT-PCR) analysis of pro- and anti-tumorigenic gene levels to identify
alterations in the total tumor microenvironment as a result of C5a expression. Cytokine
levels produced by only innate immune cells presumably have a much different profile
than if adaptive cells are present as would be the case in an immunocompetent host;
however, of importance is the effect C5a has on the cells that highly express the
appropriately receptor, constitutively.
When the total tumor samples were analyzed by qRT-PCR, many cytokine genes
evaluated did not show a difference in expression at the mRNA level: inducible nitric
oxide synthase (iNOS), transforming growth factor-beta

(TGF-~),

interleukin (IL) IL-6,

IL-lO, IL-12, interferon-gamma (IFN-y), (Fig. 7b) granzyme B, or perforin (Fig. 7c). Due
to the enhanced infiltration of NK cells into SKOV-3 C5a tumors molecules important in
their cytotoxic function were of interest, granzyme Band perforin mRNA levels were
examined but no significant difference in the levels of expression of these two genes was
noted. However, there were several genes with striking differences. Two genes, vascular
endothelial growth factor (VEGF) and arginase, which have been shown to promote
tumor growth and inhibit the local immune response, were shown to be present in
significantly lower levels in C5a expressing tumors (Fig. 7a). In addition, tumor necrosis
factor-alpha (TNF-a) expression levels of mRNA were also significantly lower in
SKOV-3 C5a tumor compared to SKOV-3 CV and WT (Fig. 7a) (Table 7). TNF-a was
originally discovered based on its tumor killing function, but since its discovery, recent
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tumor studies including human and murine, have identified this cytokine as being a key
mediator in promoting tumor growth [55, 56].
In subsequent experiments, upon tumor excision, cells were prepared and sorted
for dissecting which portion of tumor cells were responsible for the expression of certain
genes of interest (Fig 8). First, tumors were divided into tumor cells and infiltrating
leukocytes using the CD 11 b surface marker to separate these populations. Of interest was
defining the source of VEGF to identify whether the role of C5a in its reduction was
potentially directly on the immune population or indirectly leading to reduced tumor
VEGF. Following qRT-PCR of both populations, it was clear the tumor cells were the
source of VEGF and SKOV-3 CV and WT tumor cells revealed elevated levels of VEGF
mRNA expression (Fig. 8a).
In the previous tumor samples, arginase was observed to be expressed at
significantly lower levels in SKOV-3 C5a tumors (Fig. 7a); however, in the separated
samples, arginase mRNA levels were not significantly different between either cell
group, but it was determined the source of arginase in the tumor was derived
predominantly from infiltrating leukocytes (Fig. 8b). Additional mediators, TGF-p and
iNOS, were re-evaluated in the separated samples to further examine the presence of any
differences in purified leukocyte samples. No difference was observed in levels of TGF-p
in CDllb+ cells, but iNOS was shown in significantly greater levels in the CDllb+ cells
sorted from SKOV-3 CV tumors (Fig. 8c). Both VEGF and iNOS have been linked to
promoting tumor cell growth and poor survival in human studies [57,58]. The release of
C5a within the tumor microenvironment results in the reduction of iNOS in the
infiltrating leukocytes and VEGF in the tumor cells.
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Tumor associated macrophages have gained a great deal of attention in recent
years, highlighted as bearing extreme importance on shaping the tumor
microenvironment depending on macrophage phenotype which is related to the set of
factors produced by the cells [13]. Macrophages in the tumor are most often characterized
as pro-tumorigenic, expressing mediators to support tumor growth and suppress the
immune system from targeting tumor cells for destruction. Because C5a preferentially
recruited a greater percentage of macrophages to the tumor, determination of C5a
alteration of tumor associated macrophage phenotype was important. An additional
sorting experiment was required to isolate F4/80+ infiltrates from tumor cells and other
infiltrating leukocytes. The results of these qRT-PCR experiments revealed no difference
between the SKOV -3 C5a or CV tumor infiltrating macrophages in the case of VEGF,
iNOS, TNF-a or IL-12 (Fig 9). F4/80+ cells infiltrating SKOV-3 C5a tumors made
significantly less arginase, confirming lower arginase levels determined previously by
whole tumor qRT-PCR experiments. Also surprisingly revealed was SKOV-3 C5a

F4/80+ cells made significantly more TGF-~. This immune mediator is presently almost
exclusively identified as pro-tumorigenic and immunosuppressive [59-62].

TGF-~

suppresses cytotoxic T cells and enhances immune regulatory T cells and macrophages to
promote tumor growth [59], even tumor cells themselves acquire the means to produce
TGF-~.

However,

TGF-~

is also critical to cytostatic cell pathways and inhibiting

developing tumors from growing in developing stages [60-63]. The results for the above
qRT-PCR experiments have been summarized in Table 7.
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Figure 7: Immune factors expressed in the tumor microenvironment in vivo. A small portion
of the excised tumors at end point were processed in Trizol for RNA extraction and following
reverse transcription to cDNA were screened for the presence of known immune mediators
important in tumor development qRT-PCR. (a) Levels ofVEGF, arginase, and TNF-a mRNA
were significantly different between SKOV-3 C5a and the SKOV-3 CV and WT control
tumors, with each gene showing downregulation as a result of C5a in the tumor. (b) Other
important modulators of immune and tumor cells were evaluated in tumor samples, but these
showed no significant difference including IPN-y, IL-12, IL-lO, iNOS, TGF-~ , IL-6. (c) Two
important effector molecules in NK cell cytotoxicity, granzyme Band perforin, were also
evaluated by qRT-PCR after determining NK cell enhanced infiltration of SKOV-3 C5a
tumors, however, no difference was seen in the expression levels of these molecules between
tumor groups.
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Table 7

VEGF
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F4/80+
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Table 7: Summary table for SKOV-3 C5a tumors of qRT-PCR data collected for total
and sorted tumor samples. In the tumor, VEGF mRNA levels were significantly
decreased in SKOV -3 C5a total samples, and it was determined following sorting of
tumor cells and infIltrating CD 11 b+ innate immune cells that tumor cell production of
VEGF was responsible for this decrease. Arginase mRNA levels were also significantly
decreased in the total microenvironment of SKOV-3 C5a tumors, and decreased
production was found to be specifically a result of macrophage decreased arginase levels.
One final cytokine, TNF-a, was found to be significantly decreased in total SKOV -3 C5a
tumor samples compared to SKOV-3 CV and WT. Although it was determined following
sorting that the macrophage production of TNF-a mRNA was not different between the
tumor groups, it remains undetermined as to whether the change in production is a result
of tumor cell or other innate immune cells, including NK cells or neutrophils, in the
SKOV -3 C5a microenvirnoment. Production of mRNA levels of iNOS was significantly
less in the infIltrating innate immune cells of SKOV -3 C5a tumors. As well, TGF-~
mRNA levels were significantly less in macrophages isolated from SKOV -3 C5a tumors.
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CHAPTER 7
C5A ENHANCES INNATE IMMUNE CELLS TO BE ANTI-TUMORIGENIC AT
LOW DOSES

In vitro studies demonstrate the presence of C5a in transfected SKOV-3 cultures

render naive innate leukocytes more cytotoxic to tumor cells
In vitro studies were enlisted to determine whether C5a in the culture could
enhance the cytotoxicity of tumor cells by naIve leukocytes isolated from SCID spleens.
Acea system technology was used to measure the amount of cytotoxicity produced to
tumor cells by non-adherent naIve leukocytes, which includes neutrophils and NK cells.
Enhancement of cytotoxicty of C5a expressing tumor cells was demonstrated. When
compared to SKOV-3 CV and WT cells, SKOV-3 C5a cells were killed at a significantly
higher percent in the presence of the naIve leukocytes (Fig. 10). These results indicate the
C5a in the supernatant of the culture has activating potential to the added naIve white
blood cells for superior effector function in destroying tumor cells.
Cytotoxicity of naIve, non-adherent leukocytes from SCID spleen were addressed
against SKOV-3 WT in a subsequent study with cells sorted from SKOV-3 C5a and
SKOV-3 CV tumors out of growth in vivo. Gr-l+CDllb+ cells were isolated from the
tumors of endpoint mice, and these cells were cultured with naIve leukocytes in SKOV-3
WT culture, or only with SKOV -3 WT cells to determine the effect they have on immune
cell function and tumor growth. The markers used in purifying out this population are
widely used and accepted as markers for tumor infiltrating MDSCs. In the current study
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Or-1 +CD 11 b+ cells have been labeled neutrophils determined by the decrease of this
specific subset of cells in tumor bearing mice compared to naIve mice. However, in the
setting of the tumor, infiltrating immune cells are known to possess tumor promoting
immune suppressive functions. In fact, when Or-l+CDllb+ cells from both SKOV-3
C5a and SKOV -3 CV tumors were co-cultured with the naIve leukocytes that had
previously shown cytotoxicity to each tumor cell line (SKOV-3 C5a, CV, and WT) (Fig.
10) decreases in percent cytotoxicity of tumor cells occurred (Fig. 11 a). Cells isolated
from SKOV -3 C5a tumors had significantly lower suppressive effects on the naIve
leukocyte cytotoxicity. In the absence of the naIve leukocytes, neither tumor isolated Or1+CD 11 b+ population led to SKOV-3 WT tumor cell destruction. The negative
cytotoxicity demonstrated was interpreted as SKOV-3 WT cell growth in culture in the
presence ofOr-I+CDllb+ tumor infiltrated cells (Fig. lOa). Isolated cells from SKOV-3
C5a tumors were less permissive of SKOV -3 WT in vitro growth (Fig. lla).
Remaining isolated Or-l+CDllb+ cells and the CDllb+ cells also sorted from the tumor
were evaluated microscopically following cytospin, hematoxylin, and eosin staining in
order to characterize phenotype of these cells. The images of the Or-l +CD 11 b+ cells
(Fig. lIb) demonstrate that nearly all these cells are morphologically similar to
neutrophils. In tumor studies of MDSCs, defined as more immature cells and
heterogenous, whereas the population seen here is more homogenous. Additionally,
CD 11 b+ cells were evaluated by the same means, and these cells demonstrate a
predominant monocyte/macrophage phenotype, fairly homogenous as well (Fig lIc).
Even though Or-l +CD 11 b+ cells isolated from the tumor grown in vivo are
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immunosuppressive and pro-tumorigenic in nature, the neutrophils isolated from SKOV3 C5a tumors are rendered significantly less suppressive by C5a in the local tumor
microenvironment to which they were exposed.
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Figure 10: Innate immune cells from SCID show enhanced cytotoxicity to SKOV-3
C5a cells in vitro. Non-adherent immune cells isolated from SCID spleen samples
including NK cells and neutrophils kill SKOV-3 C5a expressing cells significantly
better than SKOV -3 CV and WT controls cells in vitro as evaluated by Acea assay
system after 16 hours of co-culture.
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Figure 11: Function and phenotype of Gr-l +CD 11 b+ tumor infiltrates. Gr-l +CD 11 b+
tumor infiltrating cells were sorted from SKOV -3 C5a and SKOV -3 CV tumors
following sacrifice of SCID mice at endpoint tumor growth and evaluated for
cytotoxic or suppressive effects on SKOV-3 WT tumor cells in the presence or
absence of naive non-adherent immune cells isolated from SCID mouse spleens after
28 hours. Cell histology was also evaluated. (a) Cytotoxicity evaluation by Acea
revealed the Gr-l +CD 11 b+ cells isolated from both tumors are immunosuppressive. In
the presence of WBCs, there is an evident decrease in the cytotoxicity demonstrated
by these cells. Additionally, in the absence of naive innate immune cells, co-culture of
SKOV-3 WT cells and Gr-l+CDllb+ sorted cells permit enhanced tumor cell growth.
Gr-l +CD 11 b+ cells sorted from SKOV-3 C5a tumors are significantly less
immunosuppressive and allow a more limited degree of enhanced tumor growth in the
absence of naive leukocytes. (b) Histological analysis of tumor sorted Gr-l +CD 11 b+
and CD 11 b+ cells revealed homogenous, differentiated neutrophils and
monocyte/macrophages, respectively
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Enhanced cytotoxicity of tumor cells by NK cells in the presence of C5a
C5a expression in vivo by SKOV -3 cells resulted in an increased percentage of
NK cells infiltrating into these tumors, which proves valuable due to the cancer killing
reputation of this cell subset [10, 54]. In vitro studies were performed to determine if the
C5a could provide NK cells improved cytotoxic capabilities over tumor cells in addition
to increased chemotaxis as shown by the in vivo migration into SKOV -3 C5a tumors.
Indeed, in vitro cytotoxicity studies with Acea system technology revealed NK cells
separated from nalve SCID spleen killed SKOV-3 cells releasing C5a significantly better
than SKOV-3 CV cells (Fig. 12a).
In an attempt to ascertain levels of C5a that improved cytotoxicity of NK cells
against tumors, in vitro studies utilizing NK specific target tumor cells, Yac-1 Luciferase
(Yac-1 Luc) cells, were used. Luciferase expression by these cells was utilized for
measuring specific tumor cell lysis for in vitro studies with varying concentrations of
recombinant mouse C5a (250 nglmL-0.5pglmL). These studies demonstrated that the
addition of C5a to the Yac-1INK cell culture mediated changes in NK cells to improve
the levels of specific lysis of the target cells, but only at low levels in the pglmL range
(Fig. 12b). No enhancement of cytotoxicity observed at 250-50 nglmL ranges (data not
shown). These studies were critical to understanding potential levels of SKOV-3 C5a
release of C5a into the tumor microenvironment. Through ELISA experiments for C5a
during screening and re-evaluation of C5a expressing transfected cell lines, it was
identified that the transfected SKOV-3 cells produced levels of C5a in the supernatants
between 1200-250 pglmL levels. The levels of C5a released by the cells in vivo is
probably similar to slightly lower as a result of enzyme degrading activity, and is
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confmned by NK cell cytotoxic improvement at low rather than high levels of C5a (Fig.
12).
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Figure 12: C5a promotes NK cell cytotoxicity of tumor cells. C5a present in the
culture supernatants as a result of either transfected cell production or the addition of
exogenous recombinant protein enhances cytotoxicity of tumor cells by NK. cells. (a)
NK cell cytotoxicity of SKOV -3 C5a expressing cells in greater than SKOV -3 CV
cells in vitro. (b) The presence of low levels, and not high levels, of recombinant
mouse C5a added to co-culture of NK cells and Yac-l Luc cells enhances NK cell
cytotoxicity of the tumor cells.
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CHAPTERS
EXOGENOUS C5A EXPRESSION FROM TUMOR HAS A LOCAL, NON·
SYSTEMIC EFFECT DESPITE ENDOGENOUS CRP EXPRESSION BY TUMOR
CELLS

C5a effect in the tumor is local:
Thus far, the role of C5a in the tumor microenvironment has been inconclusive,
with previously published studies drawing opposite conclusions, determining either that
C5a release from the tumor resulted in reduced growth and tumor regression [35] or that
C5a enhances immune suppression to support tumor growth [36]. We have demonstrated
here in the SKOV -3 xenograft model of ovarian carcinoma support of a proimmunogenic, anti-tumor role for C5a released in the tumor microenvironment. Both in

vitro and in vivo data suggest that C5a is acting on host cells/immune cells and indirectly
on the tumor cells to alter the cytokine milieu and enhance tumor infiltration and
cytotoxic function of innate immune effector cells to produce the reduction in tumor
progression.
Spleen and peripheral blood data collected from tumor study mice indicated the
effect of C5a release in the tumor elicits minimal changes in the periphery, and C5a
produces most changes to the tumor microenvironment cell populations and milieu.
Observing the absence of a significant systemic response in C5a tumor bearing mice
demonstrates this potent chemoattractant produced within the tumor has a local and
limited effect (data not shown). Further studies involving the use of C5a in tumor therapy
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is attractive because the systemic effects are minimal and delivery of C5a directly to the
tumor site, for instance via conjugation to monoclonal anti-tumor antibodies [4], may
lead to reduced tumor growth and tumor cell destruction by enhancing the recruitment
and activity of effector innate immune cells to the site. Determining appropriate levels of
C5a to deliver to the tumor environment is still required to obtain the desired effects on
recruitment of immune cells and infiltrating cell activity.

Circumventing CRP expression effects on complement inhibition:
Despite the abundant expression of CD55 by SKOV-3 cells [20], C5a generation
by transfected SKOV-3 cells appears to successfully by-pass inhibitory effects of CD55
by releasing its target product directly into the environment. Eliminating blockade of
CD55 on many cells in the body with antibody therapy and risking healthy tissue damage
to accomplish a similar goal is attractive. In previous studies, CRPs were identified to be
highly expressed by tumor cells and led to interference with tumor therapy efficacy [6, 7,
64]. Specifically Li et al. demonstrated CD55 expression by SKOV-3 WT cells negated
the positive effects of ~-glucan enhancement of anti-tumor monoclonal antibody therapy
as a result of CD55 activity inhibiting C5a release and subsequent chemoattraction of
neutrophils into the tumor. SKOV -3 C5a expressing cells demonstrated enhanced
recruitment of both NK cells, macrophages, and a correlation of enhanced recruitment of
neutrophils to smaller C5a expressing tumors.
Demonstrated by the in vitro growth data (Fig. 4c) and by flow data collected
showing lack of C5aR expression on SKOV-3 cells (Fig. 3c), altered in vivo growth of
SKOV -3 tumor cells expressing C5a is not a result of the activity of C5a directly on the
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tumor cells. Reduced tumor growth of SKOV-3 C5a cells is a result of the response by
host innate immune cells to C5a released into the tumor microenvironment or the culture
supernatant (Fig. 5a, 10, 12a). Also as demonstrated by the in vitro cytotoxicity assay
with innate leukocytes from SCID mouse spleen, the C5a released by the SKOV-3 cells
enhances the effector functions of neutrophils and NK cells in vitro and renders them
more cytotoxic to the tumor cells (Fig. 10). SKOV -3 cells expressing C5a in the absence
of leukocytes continue to grow, and SKOV -3 CV and WT cells are killed significantly
less well by the same leukocyte preparation. Taken together, these data suggest that once
immune cells are recruited to the tumor microenvironment, the presence of C5a locally
can activate and enhance the immune cell cytotoxic functions against the tumor and
opposes the immunosuppressive environment the tumor generally establishes.
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CHAPfER9
C5A ENHANCED RECRUITMENT OF IMPORTANT INNATE IMMUNE CELL
SUBSETS TO THE TUMOR AND ACTIVATION OF ANTI· TUMOR EFFECTS
BY THESE RECRUITED CELLS

C5a enhancement of recruitment and anti·tumor effects on NK cells in vivo and in
vitro:
C5a release from SKOV -3 cells in vivo enhanced the recruitment of innate
immune cells to the tumor as demonstrated by flow cytometry and immunofluorescent
staining on tumor samples excised from SCID mice (Fig. 6). A significantly increased
percentage of the DX5+CD 11 b+ NK cell population was found in the C5a expressing
tumors (Fig. 6a). Enhanced recruitment of the DX5+CDllb+ NK cell subset into the
tumor microenvironment is ideal because of the tumor cytotoxic and immune enhancing
potential of NK cells in an immune activating setting [10]. NK cells have been long
established as innate immune cells that recognize and kill tumor cells [38,65]. NK cell
deficiencies in animals have demonstrated a severe increase in tumor susceptibility, more
so than the lack of T cells [38].
Increased infiltration of NK cells is desirable due to the potent tumor cell killing
functions of these cells without a prerequisite priming step by an antigen presenting cell
(APC) limiting the mode of activation [10]. In solid tumors, NK cell penetration is noted
as a positive prognostic factor, but most solid tumors demonstrate inferior NK cell
infiltration [10]. Often NK cells only group in surrounding stromal tissue without closely
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interacting with the cancerous cells as is required for NK cell cytotoxicity, providing
explanation for NK cell enhancing anti-tumor therapies to be most effective for bloodborne metastases and hematological cancers [10]. C5a increases the percentage of
infiltrating NK cells, and as seen by immunofluorescence more NK cells enter beyond
stromal association (Fig 6a).
Perforin, granzyme B, TRAIL, and IFN-yhave all been associated with NK cell
killing and tumor growth suppression [10, 38]. Perforin-mediated cytotoxicity is
considered one of the most important mechanisms enlisted by NK cells to eradicate
tumor cells; however, when total tumor sample perforin and granzyme B mRNA levels
were evaluated, no enhancement of either was observed in SKOV -3 C5a tumors, but
there are additional mechanisms by which NK cells may be targeting SKOV-3 C5a cells
for destruction [65,66]. Another mechanism by which NK cells may be cytotoxic to
SKOV-3 cells in vivo is through CD40-CD40L interactions [66]. NK cell expression of
CD40L by human NK cells rendered these effector cells increasingly cytotoxic to P815
mastocytoma cells transfected with CD40 [66], and SKOV-3 tumor cells demonstrated
CD40 expression upon flow cytometric analysis following in vivo growth (observation).
NK cells can also promote other immune cell functions through the release of
potent inflammatory cytokines including IFN-yand TNF-a. SKOV-3 C5a and SKOV-3
CV and WT tumors were evaluated by qRT-PCR for the expression of both these critical
cytokines in vivo. No significant differences in IFN-yexpression were noted between the
groups, and TNF-a expression at the mRNA level was significantly decreased from the
total SKOV -3 C5a tumor microenvironment as compared with SKOV -3 control tumors.
This may indicate a negative role for TNF-a to the immune response to the tumor, as has
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been demonstrated previously [55, 56]. NK cells are a potential source of the tumor TNFa. produced at significantly increased levels in SKOV -3 CV and WT tumors, and C5a
expression in the tumor may in fact stimulate NK cells to decrease expression of TNF-a.
in this setting.

C5a enhancement of recruitment and anti-tumor effects on macrophages in vivo and
in vitro:
Macrophages have been demonstrated numerous times over, to playa dominant
role in influencing other immune cells and tumor growth depending on macrophage
phenotype determined by release of characteristic sets of factors [13, 17]. Two extreme
ends of macrophage polarization have been characterized based on the stimulating factors
used. Ml macrophages stimulated with IFN-yand/or LPS are described as classically
activated, proinflammatory, and anti-tumorigenic macrophages. To the contrary, M2
macrophages are stimulated with M-CSF, IL-4 and IL-13, or TLR ligands and are
described as alternatively activated, immunosuppressive in function, and pro-tumorigenic
[13,46]. In most settings, including the tumor, rather than extreme polarized
macrophages occurring, several subpopulations reside in the environment and possess
characteristic features of both polarized types with some variation, and usually have a
stronger profile toward one extreme or the other [13, 17]. Important interactions occur
between cells of the innate immune system, including macrophage and NK cell
interactions that are important in shaping the initial and adaptive inflammatory response.
Macrophage phenotype, dependent on the stimulating factors in the local environment are
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critical to inducing NK cell activation against an offending agent, or rather NK cell lysis
of an unproductive, polarized, autologous macrophage [67].

C5a potential enhancement of anti-tumor effects and recruitment of neutrophils in
vivo and in vitro:
As a result of the study involving

~-glucan

mediated monoclonal antibody

therapy in the SKOV-3 model identifying CD55 expression by the tumor cells as
responsible for eliminating C5a release, and as a result drastically decreasing the
infiltration of ~-glucan primed neutrophils to kill targeted cancer cells [20], engineering
SKOV -3 cells that expressed C5a was expected to negate the effects of CD55 and lead to
enhanced neutrophil recruitment without anti-CD55 therapy. However, C5a expression
from the tumor did not appear to increase the percentage of the neutrophil subset over
SKOV-3 CV and WT as it did NK cells and macrophages as expected. Percentage of
neutrophil infiltration into C5a tumors was however, in fact related to the size of the
tumor (Fig. 6c). This interesting correlation may have been related to the concentration of
C5a produced from that SKOV-3 C5a specific tumor microenvironment. Smaller SKOV3 C5a tumors may have produced lower local concentrations of C5a during initial growth
and therefore had a greater impact on neutrophil recruitment.
In the Lambris group's study of C5a production in the TC-l tumor

microenvironment, Gr-l and CDllb surface markers were used to identify the highly
suppressive, immature MDSC. In this study, we refer to cells positive for the same
markers as neutrophils. Terminology differences stem from higher levels of Gr1+CD 11 b+ cells observed in the spleens of naIve
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scm mice when compared with tumor

bearing mice (data not shown). These data indicated cells expressing high levels of these
two markers in scm mice recognized the granulocyte population as opposed to the
MDSC population, as MDSCs are known not to be expanded or suppressive in naIve
animals [68]. Additionally, the spleens of naIve and tumor-bearing mice from both
SKOV-3 C5a and control tumors weighed equal amounts, indicating there was not
significant splenomegaly of tumor-bearing mice as a result of enhanced cellular
components, namely MDSCs in tumor mice (data not shown). Lastly, cellular
morphology of Gr-l +CD 11 b+ cells sorted from SKOV -3 C5a and SKOV -3 CV tumors
revealing cells in this population were predominantly large polymorphonuclear cells (Fig.
11b). Interestingly, despite neutrophil (Gr-l+CD11b+) expression of the most abundant
levels of C5aR, there was no significant difference in the percentage of these cells
infiltrating C5a or control tumors in either group. Neutrophils may also demonstrate
varied kinetics for tumor entry and identification of the amount of this innate immune cell
infiltrating may be complicated by their short life span, even though C5a exposed
neutrophils are less susceptible to apoptosis [5].
In the TC-l study, MDSCs were further classified into two subsets based on
levels of Gr-l and CD 11 b expression. The Gr-l hiCD 11 bhi population of MDSCs are
considered polymorphonuclear-MDSCs (PMN-MDSCs) because of the similarities with
immature neutrophils, and the monocytic-MDSCs expressing Gr_lintCDllbint (MOMDSCs) with a striking resemblance to monocytes [69]. Similar to the current model, no
enhanced infiltration of tumors by PMN-MDSCs occurred although a significant
correlation was demonstrated in each model showing a relationship between the amount
of infiltrating cells (Gr-l+CD11b+ (SKOV-3 tumors) and CD11b+ (TC-l tumors) and
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tumor size. TC-l tumors demonstrated that larger tumors were more greatly infiltrated by
CD 11 b+ cells; contrastingly in the SKOV -3 model more Gr-l +CD 11 b+ cells migrated
into smaller tumors. The MO-MDSC infiltrated significantly more in C5a responsive
host, likewise F4/80+ macrophages infiltrated SKOV -3 C5a expressing tumors to a
greater extent.
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CHAPTER 10
SKOV-3 C5A TUMORS DEMONSTRATE A SIGNIFICANTLY ALTERED
TUMOR MICROENVIRONMENT, IMMUNE AND TUMOR GROWTH
MEDIATORS ALTERED AS A RESULT OF C5A EXPRESSION FROM SKOV-3
TUMOR CELLS IN VIVO

C5a modulates expression of important pro-tumorigenic factors
The significantly reduced tumor growth observed in SKOV-3 C5a tumors may
result from the increased degree of infiltration by innate immune cell subsets leading to
increased tumor cell death; however, other data indicates it is likely C5a acts locally on
the infiltrating cells. Evidence exists suggesting that C5a leads to events that alter a local
tumor environment away from being highly immunosuppressive as seen in several
changes in the cytokine milieu. Significant changes in five important tumor and immune
regulating factors exist between SKOV -3 C5a and SKOV -3 control tumors: TNF-a.,
iNOS, VEOF, arginase, and TOF-p.
TNF-a. is an important proinflammatory cytokine playing a key role in immunity
and inflammation, as well as mediating communication between cells [55,56]. This
mediator is a type II transmembrane protein, part of a superfamily of ligands, is soluble
and possesses two different receptors, TNFRI and TNFRII. It is generated in the cell as a
pro-peptide that is membrane bound. Following cleavage of the pro-peptide by a specific
activating enzyme, TNF-a. is secreted in its soluble active form, but the pro-peptide form
also has limited functional activity upon cell-cell contact. Active TNF-a. can regulate
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several separate cell functions by initiating signaling through multiple pathways
including pro-apoptotic, anti-apoptotic, and NF-1d3 pathways[55]. The cytokine is
produced predominantly by macrophages, but has also been found to be produced in
th

other cells including tumor cells and NK cells [10,55]. During the early 20 century,
surgeon Dr. William Coley developed a systemic treatment for his cancer patients
containing bacterial endotoxin known as 'Coley's mixed toxins' that was highly effective
in treating patients with various types of tumors. Later it was discovered the mechanism
by which Coley's mixture was effective in leading to tumor death was a direct result of
endotoxin stimulated macrophage production of TNF-a.
Ovarian tumors have been demonstrated by in situ hybridization and IHC to
express TNF-a in tumor cell islands, not infiltrating immune cells. In this setting, the
constitutive expression of TNF-a was found to be pro-tumorigenic and associated with
poor patient survival and therapy resistance [56]. TNF-a in other cancer studies was
found expressed by tumor associated macrophages or MDSCs, production by these cells
led to apoptosis of activated anti-tumor T cells and enhanced tumor growth [70]. In our
tumor studies, TNF-a is observed in elevated levels in SKOV -3 CV and WT tumors but
significantly lower levels in SKOV-3 C5a expressing tumors, as seen by qRT-PCR. Total
tumor was processed for the qRT-PCR data acquired, consequently the cellular source of
the TNF-a is not specifically identified. However, as a result of subsequent qRT-PCR
experiments on sorted tumor populations, F480+ cells from SKOV-3 C5a and SKOV-3
CV tumors appear to have generated similar quantities of TNF-a at the mRNA levels.
These results indicate elevated TNF-a may be generated instead by the tumor cells
themselves, NK cells, or neutrophils [10,56, 71]. TNF-a release may be restricted
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through a C5a mediated effect on innate immune cells, or an indirect effect of C5a may
exist on tumor cells resulting in the near elimination of TNF-a. expression via a C5amediated mechanism resulting in an infiltrating immune cell activity or expression of
factors that acts on tumor cell TNF-a. production. The current SKOV-3 C5a model may
demonstrate the capacity of C5a treatment to reduce the tumor promoting effects of TNFa. by reducing its expression from innate immune cells or cancer cells in vivo.
iNOS is induced in some tumor cell lines by elevated levels of TNF-a. or other
cytokines [57, 72]. In SKOV-3 CV and WT tumors, increased TNF-a.levels in the
microenvironment may have stimulated cells in the infiltrating immune population
(CDllb+ cells Fig. 8c) to generate iNOS which amplifies the pro-tumorigenic effect of
TNF-a. [57]. Nitric oxide (NO) produced in tumors can have two main sources: it may be
continuously expressed by tumor or stromal cells as cNOS (constitutive nitric oxide
synthase) or as iNOS by infiltrating myeloid cells. A distinct isoform of nitric oxide
synthase, iNOS, is uniquely produced as a result of stimulation by cytokines, is expressed
in nearly every cell type, and is capable of producing micromolar concentrations of NO
for extended amounts of time [72]. NO is a lipophilic molecule and easily migrates across
cell membranes to act intracellularly, and signaling and post-translational modifications
lead to anti-apoptosis and increased cell growth of recipient cells [72]. NO is a shortlived molecule; however, iNOS can induce sustained levels of NO, expanding the
duration and levels of NO in the environment [57].
Increased iNOS through TNF-a. induction is a characteristic of gynecological,
solid tumors, such as ovarian cancer [56]. The initial publication of elevated iNOS
detected from gynecological tumors demonstrated the expression was localized to tumor
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cells without any identified in surrounding normal cells [73]. Further studies in malignant
CNS tumors revealed a strong association between high tumor grade and elevated iNOS
levels, localized to tumor regions of hypoxia near necrotic areas [57]. Other clinical
studies evaluating melanoma patients for iNOS expression revealed tumor iNOS levels
were related to survival, with tumor expression of iNOS resulting in significantly
decreased survival, compared to iNOS negative tumor patients [57]. Additionally, a
clinical study of breast cancer including 104 specimens demonstrated increasing iNOS
expression with increasing disease severity. No iNOS was observed in benign lesions;
however, over 3/4 in situ carcinomas and nearly 2/3 of invasive disease grade tumors
stained positive for iNOS [74].
Tumor promoting mechanisms of iNOS are likely mediated through the
production and activity of NO promoting increased growth of tumor and stromal cells, as
well as increasing VEGF and vascular activity [57, 58]. iNOS levels present in SKOV-3
CV and WT tumors potentially promote tumor vascularization through induction of
VEGF expression in the tumor. Also, NO is a major macrophage effector molecule
stimulated to be released under inflammatory conditions. Macrophage NO can be
cytotoxic to tumor cells; however, NO produced by the infiltrating macrophage can also
be cytotoxic to anti-tumor lymphocytes [72]. Immune inhibition by iNOS was found to
be stronger than tumor cell cytotoxic effector functions; therefore macrophage NO had
dramatic negative effects on the survival of anti-tumor CD8+ T cells in a murine tumor
model. SKOV -3 CV and WT potentially generated NO, through elevated levels of iNOS,
may enhance tumor growth by promoting angiogenesis and invasion or the preferential
destruction of anti-tumor immune cells [72].
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In the absence of C5a release in the tumor, TNF-a, iNOS, and VEGF production
can be exploited by the tumor to promote growth. As previously acknowledged, TNF-a
produced at low levels in tumors can lead to increased expression of iNOS [55] and both
of these factors have been shown to lead to proangiogenic factor VEGF induction [55,
75]. VEGF and its role in angiogenesis and tumor neovascularization is exploited by the
tumor and is absolutely critical to its growth [76]. Within the tumor microenvironment,
VEGF has been shown to promote angiogenesis in vivo [75, 77], promoting tumor growth
by enhancing nutrient delivery to developing parts of the cancer. Tumor cells themselves
produce VEGF, and factors released from host cells in the tumor can enhance tumor
expression ofVEGF [77]. Studies involving the administration with anti-VEGF
antibodies in two xenograft models of human colon and colorectal cancer (SW480 and
DLD-l cell lines) revealed the proangiogenic effect in the tumors was predominantly
mediated by VEGF [77].
In other studies, tumor associated cells stimulated with various inflammatory
cytokines, such as TNF-a, can lead to enhanced VEGF production and release in the
tumor microenvironment resulting in increased tumor growth via angiogenic
enhancement in a murine colon cancer model [75]. Sorting experiments in the current
model reveal that it is the tumor cell population and not the immune infiltrating CD 11 b+
cells that express significantly more VEGF (Fig. 7a). C5a release in SKOV -3 tumors
enhances an immune response that inhibits the promotion or baseline production of
VEGF by the tumor. Due to the lack of C5aR expression on tumor cells, the mechanism
of C5a is indirect, but likely mediated through significantly decreased levels of TNF-a
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and/or iNOS release by tumor cells or infiltrating C5aR expressing innate immune cells
activated by local C5a.
The lack of TNF-a. and iNOS in SKOV -3 C5a tumors may be sufficient to inhibit
VEGF signaling in the tumor cells; however, there is an additional mechanism by which
C5a may be acting to inhibit tumor VEGF. C5a has previously been shown to play an
important role in negative regulation of neovascularization and angiogenesis as a result of
hypoxia [78]. In a murine model for retinopathy of prematurity (ROP), the Lambris group
demonstrated C3 and C5aR deficiency, as well as C5 blockade and C5aR antagonism led
to enhanced pathological angiogenesis. In this model, macrophages were found
responsible for the anti-angiogenic effect of C5a rather than endothelial cells of the
vasculature which also express C5aR. C5a stimulation of macrophages resulted in
increased secretion of soluble VEGFRI (sVEGFR1) [78]. Release of sVEGFRI inhibits
VEGF signaling important in angiogenesis. Depletion of macrophages in C3 or C5aR
deficient mice reversed angiogenic enhancement demonstrated in undepleted complement
deficient mice [78]. Additionally, administration of C5a peptide led to a decrease in
pathological neovascularization in WT ROP mice, as well as C3 deficient ROP mice that
previously showed significantly more angiogenesis [78]. Other cells of the innate
immune system, including neutrophils have been shown to be important in the regulation
of angiogenesis in tumors [71]. C5a inhibition ofTNF-a. and iNOS from tumor or innate
immune cells, or induction of sVEGFR 1 release may be alterations of the tumor
microenvironment occurring to reshape the tumor promotion of the VEGF response in the
microenvironment of aSKOV -3 CV or WT tumor without sufficient C5a present.
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A striking observation consistently occurred during each in vivo tumor study with
SKOV -3 C5a and SKOV -3 CV and WT cells. The majority of SKOV -3 CV and WT
tumors would become outwardly necrotic with the production of hardening and scabbing
(Fig. 5d). Necrotic tissue possesses tumor promoting and proinflammatory properties
different from apoptotic cells. Unlike the apoptosis pathway of cell death, necrotic cells
have been demonstrated to result from an underlying genetic mechanism, rather than by
random means [9]. Necrotic cells release proinflammatory signals and actively direct
immune cells to the site of necrosis in the tumor microenvironment [9]. Cancer cell death
by necrosis may seem useful in eliminating tumor cells: however, subsequent events
indicate death by necrosis may end up benefiting the tumor [9]. Another group reported
necrotic tumor cells stimulated MDSCs in the tumor to release molecules that induce
apoptosis in anti-tumor T cells [70]. Arginase was an important component of this
negative effect on the anti-tumor T cells produced by the infiltrating MDSCs [36, 70].
Arginase is an enzyme produced by innate immune cells that depletes arginine, an
amino acid required for the activation of adaptive immune cells. Upregulation of arginase
expression to high levels in tumor associated macrophages has been demonstrated [79].
SKOV-3 CV and WT tumors contain significantly higher levels of arginase mRNA than
SKOV-3 C5a tumor cells. The F4/80+ infiltrates in SKOV-3 CV tumors are the source of
elevated arginase. Arginase expressed by MDSCs to inhibit anti-tumor responses at the
tumor edge, the site at which growth occurs has been observed [14]. Being that a major
role in the suppressive function of arginase is arginine depletion of proliferating and
activating anti-tumor T cells, the negative role in the SCID mouse must include another
mechanism. MDSC suppressive factors predominantly include arginase and iNOS [14],
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and the production of arginase is critical to generating the suppressive molecules of
MDSCs, reactive oxygen and nitrogen species (ROS and RNS) [36]. Arginase dependent
generation of reactive species can result in the enhanced mutagenesis in the tumor and
progression.
Interestingly in the SKOV-3 CV mice with increased tumor growth, TNF-a. and
iNOS are elevated. These two factors released by macrophages are commonly associated
with the Ml anti-tumor phenotype of macrophages. Even though TNF-a. was previously
considered anti-tumorigenic, it has been demonstrated to promote tumor growth by
working on macrophages and destroying the mechanism by which these cells respond to
suppressive cues, resulting in an acute, and sometimes chronic inflammatory response
generated to which tumors respond well [13]. Macrophages are a critical component to
the pro-tumorigenic inflammation established as a result of the generation of NO
(through iNOS) and its mutagenesis of adjacent cells perpetuating tumor progression
[13]. Increased infiltration of tumors by macrophages has been associated with poor
survival in tumor patients many times over [80, 81]. Macrophage generation of TNF-a.
has been shown to lead to iNOS production, and iNOS is capable of producing a wide
range of NO concentrations in the local environment that can last anywhere between
seconds to days to sustain tumor growth and promote VEGF production and tumor
vasculature [57]. As well, the increased levels

ofTGF-~

detected in SKOV-3 C5a tumors

are more often associated with the immunosuppressive phenotype of M2 pro-tumorigenic
macrophages.
The final immune and tumor modulating factor that was recognized as having
altered levels in the SKOV -3 model following introduction of C5a was TGF-~, however;
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this typically immunosuppressive mediator was generated in significantly higher levels in
the SKOV -3 C5a tumors.

TGF-~

has been found to have tumor stage dependent effects

[62]. Expression in tumor early during development has a cytostatic/tumor suppressive
effect and is proinflammatory, leading to the production of cytokines such as IL-6, IL-l,
TNF-a and IL-17 [63]. Mohammed et al.looked at the role ofTGF-~ in benign
premalignant tumors by overexpression of the protein in the skin of epidermal squamous
lesions using inducible TGF-~ transgenic mice. In this study, they found expression of
TGF-~

led to a proinflammatory response, increased infiltration of inflammatory cells

into the lesion and tumor draining lymph nodes, resulting in tumor regression. However,
the proinflammatory response was not completely responsible for the regression seen,
and it was determined that the cytostatic program elicited by TGF-~ overexpression was
also having an effect directly on the tumor cells to reduce tumor development [63].
Additional evidence exists suggesting TGF-~ in the tumor does not equate
immunosuppression and tumor development. TGF-~ anti-proliferation effects on tumor
cells, a result of prevention of Retinoblastoma protein (Rb) phosphorylation or by
suppression of c-myc, block cell cycle advancement through Gl [76]. Some tumors evade
suppression by this mechanism by downregulating or altering TGF-~ receptor expression
[76]. The TGF-~II receptor is commonly mutated and functionally inactivated in colon
and gastric carcinomas lacking replication error-repair. Germline mutations in the gene
encoding

TGF-~II

receptor occurs in hereditary nonpolyposis colorectal cancer resulting

in non-respondent tumor cells to the cytostatic effects mediated by TGF-~ [60]. Lastly, in
human cell studies involving activin A which is a member of the TGF-~ superfamily, was
shown to stimulate macrophages toward an Ml phenotype [82]. In the SKOV-3 model,
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TGF-~

may be predominantly working against SKOV-3 C5a cell growth by negatively

regulating advancement of tumor cells through the cell cycle.
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CHAPTER 11

CON CENTRA TION OF C5A RELEASEDIPRESENT IN THE TUMOR
MICROENVIRONMENT IS CRITICAL IN THE DETERMINATION OF
TUMOR GROWTH OR SUPPRESSION

Concentration levels critical to other mediators shown to be important in tumor
growth outcome:
Previous studies have shown benefit to TNF-a in eliminating tumor cells [55],
and iNOS is a key mediator produced by macrophages polarized toward an Ml
phenotype thought to have anti-tumor characteristics [13], but in the SKOV-3 model,
both are associated with increased tumor progression (Fig 5). Important to the specific
effect of an immune cell and tumor growth mediator is concentration levels in the tissue.
The highest levels of iNOS correlated with most poorly differentiated tumor cells

(~250

pmollminlg of tissue) [73]. The concentration of NO produced by iNOS remains in
question; however, based on evidence from previous studies, apparently intermediate
ranges of NO that are not prolonged in the microenvironment provide ideal tumor
assistance [57]. Levels of NO concentration ranging between 50-100 nM possess positive
survival influences on tumor cells [57]. In vitro study shows when those levels are
breached and overwhelming amounts of NO are produced surpassing 400 nM
concentrations, tumor cell promoting effects are lost [57]. Additionally, prolonged low
levels of NO, in the range of 1 nM, also appear to be detrimental to tumor cell survival
[57].
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Ranges existing within the significantly larger control SKOV-3 tumors promote
tumor cell survival or initiate the other pro-tumorigenic features of iNOS including
transformation of epithelial cells and iNOS and TNF-a activation of ongcogenes [55].
Results of targeting the mediator of 'Coley's mixed toxins' led to trials and treatment of
cancer patients with TNF-a; however, successful TNF-a treatment of patients was found
to only be sufficient in high doses, which was associated with serious adverse effects.
Contrastingly, low dose TNF-a is a feature of tumor cell cytokine production, and in the
setting of the tumor microenvironment, TNF-a at lower levels promotes tumor cell
survival, proliferation and protection from apoptosis, immune evasion, and angiogenesis
[55, 56, 76].

C5a concentration effects on tumor growth and the infiltrating innate immune cells:
Even though similar infiltration patterns exist between TC-l and SKOV-3 tumors
in MO-MDSC and macrophage as well as PMN-MDSC and neutrophil subsets, we
hypothesize tumor growth outcomes differ tremendously due to C5a concentration levels
generated in the two models and the impact this has on surface C5aR expression and cell
activity in response to C5a signaling. As a G-protein coupled receptor, C5aR is
continuously recycled from surface expression to an internalized form based on the level
of stimulation. Important findings of C5aR internalization in tumor infiltrating MDSCs in
the TC-l model reveal that none of the C5aR expressed by tumor MDSCs is expressed on
the surface, as it is only seen following permeabilization of these cells before staining
[36]. Fairly high percentages of C5aR was still found to be expressed on Gr-l +CD 11 b+
and CDllb+ cells infiltrating SKOV-3 tumors (Fig 6c). Gr-l+CDllb+ surface
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expression of C5aR pertains to C5a levels and effects cell functionality; levels of C5a and
function of responding cells are directly related to the sensitivity and ability of expressing
cells to respond [5]. However, the observation that more neutrophils are found in smaller
C5a expressing tumors may highlight an important role and degree of C5aR expression
responsiveness or sensitivity to C5a signaling for these effector cells in recruitment to
tumors to suppress maximal growth (Fig. lOa). The difference in neutrophil percentages
found in smaller tumors vs. larger tumors expressing C5a may be related to the actual
concentration of C5a in the environment which may vary once in vivo during tumor
establishment.
During sepsis, an over-activated complement system. namely the release of high
levels of C5a, disables innate immune cells, decreasing phagocytic function and resulting
in an overall immunosuppressive state [37]. Due to the high levels of C5a released during
a septic response, the amount of surface C5aR on cells is critical to the susceptibility of
that cell to the over-activating levels of the anaphylatoxin [5]. Neutrophils express
abundant C5aR and these levels make the cell increasingly sensitive, while
monocytes/macrophages express lower amounts of the receptor and are, therefore less
susceptible and overall more resistant to over-activation by C5a [37].
Additionally studies of in vivo sepsis models demonstrated higher levels of C5aR
expression on neutrophils was positively correlated with survival because the mice are
more sensitive to C5a stimulation. It is not clear; however, whether the increased surface
expression of C5aR was a result of lower C5a concentrations generated during sepsis of
these mice or if the neutrophils possessed a receptor recycling efficiency advantage [5].
In the compared model systems, it is arguable that C5a concentrations produced by
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SKOV -3 C5a tumors are lower, but effective because enhanced in an isolated area. While
TC-1 tumor cell growth in vivo may not produce over-activating levels of C5a throughout
the host, these cells express Human Pappiloma Virus (HPV -16) protein E7 which
presumably mounts a large antibody response in the foreign host that results in the
classical activation of complement reported. This may actually lead to relatively higher
local concentrations of C5a being generated, potentially leading to over-activation of
infiltrating cells by C5a.
Quantitation of the chemoattractant and how quickly it is degraded by enzymes in
the environment complicates pinpointing a clear role for C5a in the tumor and the critical
concentration threshold. It has been demonstrated to this point that C5a expression from
tumor cells can lead to the extreme opposite effects on tumor growth, but taken together
the evidence generated between the tumor C5a studies (and the current work) support the
hypothesis that C5a concentration holds the key to the response generated to tumor C5a
released locally in vivo. During the generation of C5a expressing transfected SKOV-3
cells, we showed by ELISA for unconcentrated culture supernatants from these cells
following in vivo passage to contain low nglmL-pg/mL levels of C5a «1.2 nglmL).
According to the study using the C5a transfected EMT6 cells, low and high levels
of C5a released from the tumor cells yields opposite results on tumor growth. However,
this study never legitimately quantified C5a concentration released by the transfected
tumor cells or the number of cells from which the supernatant had been collected and
based concentrations of C5a on the extent of 1774 macrophage cell line recruitment to
culture supernatants. The chosen transfected cell line for the studies with identified low
levels of C5a released, based on the chemotaxis assay, elicited nearly 10 times the
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number of 1774 cells migrating to the same clone's supernatant following only one
additional day of tumor cell culture. SKOV -3 C5a transfected cells demonstrated changes
in C5a concentration over the course of culturing in vitro. C5a concentration, as
measured by ELISA went from 766 pglmL to 1140 pglmL over two days which may be
sufficient a change to produce chemotactic variation in responder cells. These results
complicate concentration concerns, especially when considering unknown changes that
may occur in vivo.
It appears, at least in vitro, C5a may increase in culture supernatant overtime.
Whether this is due to the accumulation of C5a over the incubation time period, more
cells present over more time, or cells under certain growing conditions such as increased
confluency or more acidic media may produce more C5a. C5a accumulation is less likely,
even in vitro, as a result of enzymes in the serum that likely inactivate C5a to the C5a

desArg degradation product. Another explanation lies in the activity of C5a desArg in
chemoattracting cells in vitro [3]. Recalling the receptor is internalized to regulate the
response of receptor expressing cells based on available ligand, the migration response
curve of 1774 cells or innate immune cells to C5a concentrations should be Bell-shaped
with intermediate concentrations producing the greatest migration (Fig. 13). It is difficult
to determine levels of C5a the clone used for the EMT6 studies consistently expressed in

vitro or if variations day to day/passage to passage occurred. Additionally, with the
release of C5a in vivo, the rapid cleavage to C5a desArg occurs and even though it has
demonstrated chemotactic stimulation of C5aR expressing cells, this cleavage product
possesses less abundant proinflammatory role, maintaining only 10% of activity [5].
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Figure 13: Critical levels of C5a concentration: (A). Suboptimal C5a levels:
Non-inflammatory inducing, spontaneous, basal levels of complement
activation release of C5a. (B) Optimal C5a levels: Inflammatory response to
pathogen/injury, potent and effective, activation of complement and C5a
release that enhances immune functions of phagocytes, quick resolution of
affected tissue. (C) Over-activating C5a levels: Sepsis, paralysis of phagocyte
effector cells, renders cells non- responsive to inflammatory environment.
As is the case for TNF-a and iNOS leading to NO production in tumor studies,
concentration levels of these factors possess opposing effects on tumor growth. The
contradicting work we and others [35, 36] have demonstrated in animal models involving
tumor C5a and the effects it has on tumor growth and infiltrating cells may be due to the
levels of C5a in the environment (Fig. 14). High levels (such as nglmL or higher) may
lead to enhancement of an inflammatory setting that favors generation of factors by the
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tumor and infiltrating cells to perpetuate an environment ideal for promoting the tumor
growth, angiogenesis, and suppressing the anti-tumor response. Conversely, low levels
(such as pglmL) of the complement protein may enhance infiltration of immune cells, and
upon entry into the environment, C5a at low levels stimulates a more powerful anti-tumor
immune response (Table 2 and Fig. 1).
As a result of the inconsistencies generated over a definitive role for C5a in the
tumor setting, further studies are imperative in order to dissect what clearly leads to an
anti-tumor response mediated by C5a. Usage of C5a is attractive due to the fact that it is a
small molecule and could be easily incorporated into an existing therapeutic protocol
such as monoclonal antibody therapy. Additionally, as shown here, little adverse side
effects would be anticipated as to its limited local effect and rapid degradation to a
significantly less potent form in vivo. By linking C5a to Herceptin, for example in the
treatment of breast cancer, following administration into patients, there are several
concerns to consider. There may be a systemic response to C5a when it is present in the
circulation leading to adverse events. It may also be degraded by serum enzymes, and
upon binding of the Herceptin-C5a complex in the tumor, C5a desArg may be less
effective, or it may still be beneficial in improving therapy [4]. Additionally, rather than
using a form of C5a that can be cleaved, the proven stable peptide agonist of C5a [83]
may be linked to a therapeutic antibody and administered, maintaining C5a functional
activity. However, this could also have adverse effects. In some cases, C5a may be
locally administered directly into the tumor so the local effect observed in the tumor
model may be duplicated in treatment of patients, but this method likely will not be
useful in metastatic disease.
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It is also important to consider the effects, yet unclear on the adaptive immune

response, as a result of the effects of C5a on the innate immune response and directly on
C5aR expressing adaptive immune cells. In the setting of an immunocompetent mouse,
the decrease in the levels of TNF-a. and iNOS may remain beneficial in reducing tumor
growth. Alternatively, whereas low levels of TNF-a. may negatively affect the activation
status of infiltrating T cells, the reduction in iNOS may be protective. In addition, the
elevated levels of TGF-~ observed in the SKOV -3 C5a tumor infiltrating macrophage
population, if maintained in the immunocompetent mouse may be tremendously
detrimental by enhancing the T regulatory cell and immunosuppressive response. Future
directions of C5a study in the tumor are imperative to define the effects on the adaptive
immune response in the tumor and should focus on understanding quantitative analysis in
vitro and in vivo and defining a critical threshold for the anti-tumorigenic effects of C5a
as well.
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Figure 14: Role of C5a in the tumor microenvironment is concentration dependent.
Schematic model of current and published studies revealing critical role for C5a in the
tumor microenvironment emphasizing the critical dependence on concentration levels the
effect the protein may have. (a) SKOV-3 C5a tumor microenvironment hypothesized to
release and maintain consistent low (ng-pg/mL) levels of C5a, significantly enhances
infiltration of effector NK cells and anti-tumor macrophages. Recruited NK cells are
activated to induce superior cytotoxicity of SKOV-3 tumor cells. Additionally, increased
numbers of recruited macrophages generate significantly higher levels of TGF-p to
promote anti-tumor inflammation and effectively arrest tumor cell division. (b)
Conversely, in the SKOV -3 CV microenvironment, lack of C5a results in significantly
increased levels of VEGF, TNF-a, iNOS, and arginase which have all been shown to
play important roles in tumor progression and immune suppression. (c) In order to
rationalize discrepancies in the literature over the role of C5a in the tumor, a critical
component that may offer an explanation of identifying opposite functions of an immune
mediator is drawn from its local concentration. Generating or releasing abundant C5a
may result in an immune over-activating phenotype, paralyzing responding cells from
functioning in a productive anti-tumor response as a consequence of overstimulation.
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